Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity or performance. There can be no assurance that the forward-looking statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, prospective investors should not place undue reliance on forward-looking statements. In particular, you should consider the following factors, as well as those described in "Risk Factors" below:

• changes to existing or new laws or regulations which may negatively impact the Company's operations, any of which may be applied or enforced retroactively;

  	•	we may be unable to implement our business plan of operations as anticipated; our plans for product development and branding may not result as we anticipate or at all; we may be unable to meet our existing and future financial obligations and we may suffer a significant negative effect on our business plan and operations, including our ability to develop new products and continue our current operations; consumer perceptions of the cannabis industry may change regarding perceived medical benefits, safety, efficacy and quality of the cannabis distributed for medical purposes to such consumers; we may be unable to obtain the licences we have applied for and expect to obtain; and we may be unable to generate sufficient revenue and/or raise adequate future financing necessary for our continued operations. changes to existing or new laws or regulations which may negatively impact the Company's operations, any of which may be applied or enforced retroactively;
  	•	we may be unable to implement our business plan of operations as anticipated;
  	•	our plans for product development and branding may not result as we anticipate or at all;
  	•	we may be unable to meet our existing and future financial obligations and we may suffer a significant negative effect on our business plan and operations, including our ability to develop new products and continue our current operations;
  		consumer perceptions of the cannabis industry may change regarding perceived medical benefits, safety, efficacy and quality of the cannabis distributed for medical purposes to such consumers;
  	•	we may be unable to obtain the licences we have applied for and expect to obtain; and
  	•	we may be unable to generate sufficient revenue and/or raise adequate future financing necessary for our continued operations.

  These and other factors may cause our actual results to differ materially from any forward-looking statement. The forward-looking statements in this registration statement speak only as to the date hereof. Except as required by applicable law, including the securities laws of the United States and Canada, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

  ABOUT THIS ANNUAL REPORT

  As used in this annual report, the terms "we", "us" and "our" refer to Adastra Holdings Ltd., a British Columbia corporation, and its direct and indirect subsidiaries, unless otherwise specified.

  Our financial statements and other financial information are prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board, or "IFRS", in Canadian dollars. None of our consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, and our financial statements may therefore not be comparable to financial statements of United States companies.

  In this annual report, the terms "dollar", "$" or "CAD$" refer to Canadian dollars and the term, "US$" refers to United States dollars.

  The share and per share information in this annual report, other than in our consolidated financial statements and the notes thereto, or where referred to as "pre-consolidated", reflects a consolidation of our issued and outstanding common shares on the basis of one new common share for three old common shares which was completed on April 9, 2021.

  2

  ---

  PART I

  Item 1.  Identity of Directors, Senior Management and Advisers

  Not applicable.

  Item 2.  Offer Statistics and Expected Timetable

  Not applicable.

  Item 3.  Key Information

  A. Selected Financial Data

  The selected historical information presented in the table below for the years ended December 31, 2021,2022, and 20202021 are derived from the audited consolidated financial statements of Adastra for such periods and have been prepared in accordance with IFRS as issued by the IASB. The selected financial information presented below should be read in conjunction with the audited consolidated financial statements and the notes thereto of Adastra filed herewith, and with the information appearing under each of Item 4 - "Information on the Company" and Item 5 - "Operating and Financial Review and Prospects" of this Form 20-F. All financial data presented in this Form 20-F are qualified in their entirety by reference to the audited consolidated financial statements and the notes thereto filed with this Form 20-F.

  		FYE 2021 (IFRS)			FYE 2020 (IFRS)			FYE 2022 (IFRS)			FYE 2021 (IFRS)
  		$			$			$			$
  Gross Revenue		5,628,616			2,499,355			18,131,826			5,628,616
  Excise Taxes								(4,836,748	)		-
  Cost of Sales		(3,684,925	)		(1,713,774	)		(7,183,029	)		(3,684,925	)
  Gross Profit		1,943,691			785,581			6,112,049			1,943,691
  Operating expenses		(4,335,429	)		(7,950,595	)		(6,912,045	)		(4,335,429	)
  Net loss and comprehensive loss		(2,749,939	)		(7,615,864	)		(4,281,639	)		(2,749,939	)
  Total assets		28,755,450			13,736,950			31,803,945			28,755,450
  Current liabilities		5,341,267			3,590,794			12,660,207			5,341,267

  Adastra has never declared or paid any cash or other dividends.

  B. Capitalization and Indebtedness

  Not applicable.

  C. Reasons for the Offer and Use of Proceeds

  Not applicable.

  D. Risk Factors

  An investment in our common shares involves a number of very significant risks. You should carefully consider the following risks and uncertainties in addition to other information in this annual report in evaluating our company and our business before purchasing our common shares. Our business, operating results and financial condition could be seriously harmed due to any of the following risks. The risks described below are not the only ones facing our company. Additional risks not presently known to us may also impair our business operations. You could lose all or part of your investment due to any of these risks.

  3

  ---

  Risks Related to Our Business

  Regulatory risks

  The industry in which we operate requires compliance with federal, provincial, and local laws and regulations, which could include, among others, laws and regulations relating to cannabis, controlled substances, personally identifiable information, wage and hour restrictions, health and safety matters, consumer protection and environmental matters. Our business objectives are contingent upon, in part, compliance with regulatory requirements enacted by these governmental authorities and regulatory bodies and obtaining all regulatory approvals, where necessary, for the delivery of its services and the services delivered by those regulated professionals within its network. We cannot predict the time required to secure all appropriate regulatory approvals for such services. Compliance with such laws and regulations may be costly and a failure to comply with such laws and regulations could result in fines, penalties, litigation and other liability that could materially adversely affect us.

  Furthermore, although our operations are currently carried out in accordance with all applicable rules and regulations, no assurance can be given that new rules and regulations will not be enacted or that existing rules and regulations will not be applied in a manner which could limit or curtail our ability to conduct its business, including the development of new or existing markets and products. We have little or no control over potential changes to laws or regulations that may affect its business. Changes in applicable laws and regulations are unpredictable and could have a material adverse effect on our business, results of operations and financial condition.

  Additionally, governmental regulations affect taxes and levies, healthcare costs, energy usage and labor issues, all of which may have a direct or indirect effect on our business, clients or suppliers. Changes in these laws or regulations, or the introduction of new laws or regulations, could increase the costs of us doing business, or our customers or suppliers, or restrict our actions, causing us to be materially adversely affected.

  Laws, regulations and guidelines relating to controlled substances

  We are not currently undertaking any activities involving controlled substances, nor do we intend to undertake any activities regarding controlled substances at this time. However, as a holder of a Controlled Substance Dealer's Licence issued by Health Canada, we are subject to regulatory and statutory obligations relating to controlled substances. The Controlled Drugs and Substances Act is Canada's federal drug control statute. Controlled substances are categorized into eight Schedules based upon their perceived danger. Schedule 1 substances are deemed to have the highest potential for abuse and carry the most severe penalties for violations - the severity of the penalties decreases for subsequent scheduled substances. The CDSA generally prohibits all uses of controlled substances unless an exemption is granted under Section 56 of the CDSA or the regulations allow otherwise, including through a clinical trial. The Canadian Minister of Health can grant exemptions under Section 56 of the CDSA to use controlled substances if it is deemed to be necessary for a medical or scientific purpose or is otherwise in the public interest.

  Despite the general prohibition on controlled substances, the Food and Drug Regulations and Narcotics Control Regulations allows authorized persons to obtain a dealer's licence to possess, produce, sell, import/export, and transport certain controlled substances. These regulations contain strict requirements as to the handling of controlled substances, including where the controlled substance is stored and processed, who has access to the controlled substance, who may purchase or receive the controlled substance, and the types of activities that may be performed using the controlled substance. These regulations provide a framework for expanding and monitoring the legal use of controlled substances in Canada as well as, importantly, issuing licences to dealers such as our Dealer's Licence. However, amendments to current laws and regulations governing the importation, distribution, transportation and/or production of controlled substances, or more stringent implementation thereof could have a substantial adverse impact on us. Local, provincial, and federal laws and enforcement policies concerning controlled substances are changing rapidly and will continue to do so for the foreseeable future.

  Should we choose to engage in permitted activities as authorized by our Dealer's Licence at a later date, our operations will be required to be conducted in strict compliance with the laws and regulations regarding its activities with controlled substances. We do not have any direct or indirect involvement with the illegal selling, production or distribution of any substances in the jurisdictions in which we operate and do not intend to have any such involvement at this time. However, a violation of any applicable laws and regulations, such as the CDSA, could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings initiated by the government entities in the jurisdictions in which we operate, private citizens or criminal charges. Any such violations could have a material adverse effect on our business, results of operations and financial condition.

  4

  ---

  Reliance on licences

  Our ability to produce and sell cannabis products in Canada is dependent on maintaining our licences with Health Canada. All of our licences are, or will be, subject to ongoing compliance and reporting requirements. Failure to comply with the requirements of the licences, to maintain our licences, and to renew the licences after their expiry dates would have a material adverse impact on our business, financial condition and operating results.

  If we opt to pursue commercialization strategies involving the permitted activities pursuant to our Dealer's Licence, our ability to engage in such permitted activities will depend on maintaining the Dealer's Licence with Health Canada. Failure to comply with the requirements of the licence, to maintain our licence, and to renew the licence after its expiry date may have a material adverse impact on our business, financial condition and operating results.

  Should Health Canada not extend or renew existing licences, renew existing licences on different terms, or refuse applications for new licences, our business, financial condition and operating results would be materially adversely affected.

  Our activities are subject to regulation by governmental authorities.

  Our activities are subject to regulation by governmental authorities. Achievement of our business objectives are contingent, in part, upon compliance with regulatory requirements enacted by these governmental authorities and obtaining all regulatory approvals, where necessary, for the sale of our products and services. We cannot predict the time required to secure all appropriate regulatory approvals for our products and services, or the extent of testing and documentation that may be required by governmental authorities. Any delays in obtaining, or failure to obtain regulatory approvals would significantly delay the development of markets and products and services and could have a material adverse effect on our business, results of operations and financial condition.

  3

  ---

  Doing business in the cannabis industry leaves our company subject to possible regulatory risks.

  The cannabis industry is a new industry which is highly regulated, highly competitive and evolving rapidly and psychedelicscertain controlled substances are illegal substances other than when used for scientific or medical purposes. As such, new risks may emerge, and management may not be able to predict all such risks or be able to predict how such risks may result in actual results differing from the results contained in any forward-looking statements.

  Psychedelics are Schedule III substances under the Controlled Drugs and Substances Act for which the extraction of raw materials from, or involvement in production activities are regulated federally in Canada. In order to develop our business and undertake research and development, the Company is applying for a dealer license for psychedelics which, if obtained, will allow the Company to possess and formulate psychedelics. While we anticipate being successful in this application, there is no guarantee that we will obtain a dealer license to possess and formulate psychedelics. If we are successful in this application there remain uncertainties with respect to how government regulations will impact our business with respect to psychedelics.  The Company is in the process of assessing this impact.  At present a dealer license holder can only trade with another individual who has the same license. Their activities are limited in trade and they cannot provide substances to individuals or companies as Health Canada has yet to approve psychedelics as a drug and it is currently illegal to possess psychedelics in Canada without a dealer license or other exemption.  We are confident that our application will  be successful, however, if in the unlikley event we are unable to obtain a dealer license, this will serverly limit our ability to undertake research and development in psychedelics.

  These industries are subject to extensive controls and regulations, which may significantly affect the financial condition of market participants. The plain packaging requirements and restrictions on promotion of cannabis and the restrictions on promotion of illegal substances in Canada may limit the ability to effectively advertise and promote our products and business. The marketability of any product may also be affected by numerous factors that are beyond the control of the investee companies and which cannot be predicted, such as changes to government regulations, including those relating to taxes and other government levies which may be imposed. Changes in government levies, including taxes, could reduce the investee companies' earnings and could make future capital investments or the investee companies' operations uneconomic. The cannabis industry is also subject to numerous legal challenges, which may significantly affect the financial condition of market participants, and which cannot be reliably predicted.

  The impact of various legislative regimes on our business plans and operations is uncertain. There is no guarantee that the applicable legislation regulating the manufacture, distribution, sale and promotion of cannabis will create or allow for the growth opportunities we currently anticipate.

  Acquisitions or other consolidating transactions in our industry could have adverse effects on our company.

  Acquisitions or other consolidating transactions in our industry could have adverse effects on our company. We could lose strategic relationships if our partners are acquired by or enter into agreements with a competitor, causing us to lose access to distribution, content and other resources. The relationships between our company and our strategic partners may deteriorate and cause an adverse effect on the business. We could lose customers if competitors or user of competing technology consolidate with our current or potential customers. Furthermore, our current competitors could become larger players in the market or new competitors could form from consolidations. Any of the foregoing events could put our company at a competitive disadvantage, which could cause our company to lose customers, revenue, and market share. Consolidation in the industry could also force our company to divert greater resources to meet new or additional competitive threats, which could harm our operating results.

  5

  ---

  COVID-19 Pandemic has and will continue to affect our business.

  COVID-19 outbreak continues to rapidly evolve and is causing business disruptions across the entire global economy and society. We have taken various measures to prioritize the health and safety of our employees, customers and partners, including restricted work travel and site access; improved safety & hygiene; and the requirement of nonessential staff members to work remotely. As a manufacturer of consumable and medicinal products, our practice is always to operate to global pharma-quality standards to the best of our abilities with strict hygiene practices and mandated personal protective equipment. The extent of the impact on COVID-19 on our operational and financial performance will depend on various developments, including the duration and magnitude of the outbreak, and the impact on customers, employees and vendors, all of which are uncertain and cannot be predicted at this point.

  4

  ---

  We could have issues of conflicts of interest with our directors and officers.

  Certain of the directors and officers of our company are also directors and officers of other companies, and conflicts of interest may arise between their duties as officers and directors of our company and as officers and directors of such other companies.

  Global economic conditions could materially adversely impact demand for our products and services.

  Our operations and performance depend significantly on economic conditions. The COVID-19 global pandemic and resulting government health regulations have resulted in significant reductions in global economic output and have negatively impacted global economic conditions. The ultimate impact and duration of current negative global economic conditions are highly uncertain. Uncertainty about global economic conditions could result in customers postponing purchases of our products and services in response to tighter credit, unemployment, negative financial news and/or declines in income or asset values and other macroeconomic factors, which could have a material negative effect on demand for our products and services and, accordingly, on our business, results of operations or financial condition.

  We have ongoing need for financing.

  Our ability to continue operations will be largely reliant on our continued attractiveness to equity investors. We are expected to incur operating losses as we continue to expend funds to develop our business operations. Our continued development will require substantial additional financing. The failure to raise such capital could result in the delay or indefinite postponement of current business objectives or the going out of business. The primary source of funding available to our company will consist of equity financing. There can be no assurance that additional capital or other types of financing will be available if needed or that, if available, the terms of such financing will be favorable. In addition, from time to time, we may enter into transactions to acquire assets or the shares of other corporations. These transactions may be financed wholly or partially with debt, which may temporarily increase our debt levels above industry standards.

  Ongoing costs and obligations

  Our efforts to grow our business may be costlier than we expect, and we may not be able to increase our revenue enough to offset higher operating expenses. We may incur significant losses in the future for a number of reasons and unforeseen expenses, difficulties, complications and delays, and other unknown events.

  We lack business diversification.

  The prospects for our success are dependent upon the future performance and market acceptance of our facilities, products, processes, and services. Unlike certain entities that have the resources to develop and explore numerous product lines, operating in multiple industries or multiple areas of a single industry, we do not have the ability to immediately diversify or benefit from the possible spreading of risks or offsetting of losses. Again, the prospects for our success are dependent upon the development or market acceptance of a very limited number of facilities, products, processes or services.

  We may encounter issues with managing growth.

  Any expansion of our business may place a significant strain on our financial, operational and managerial resources. There can be no assurance that we will be able to implement and subsequently improve our operations and financial systems successfully and in a timely manner in order to manage any growth we experience. There can be no assurance that we will be able to manage growth successfully. Any ability of our company to manage growth successfully could have a material adverse effect on our business, financial condition and results of operations.

  6

  ---

  We rely on key consultants.personnel.

  There canIf we are unable to attract and retain key personnel, it may not be no assurance that any of our consultants will remain with our company or that,able to compete effectively in the future, theymarket. Our success has depended and continues to depend upon its ability to attract and retain key management, including our CEO, CFO and technical experts. We will not organize competitive businessesattempt to enhance our management and technical expertise by continuing to recruit qualified individuals who possess desired skills and experience in certain targeted areas. Our inability to retain employees and attract and retain sufficient additional employees or accept opportunities with companies competitive with us. We depend on a number of key officersengineering and directors the loss of any one of whomtechnical support resources could have ana material adverse effect on our company.business, results of operations, sales, cash flow or financial condition. Shortages in qualified personnel or the loss of key personnel could adversely affect our financial condition, results of operations of the business, and could limit our ability to develop and market our products. The loss of any of our senior management or key employees could materially adversely affect our ability to execute our business plan and strategy, and we may not be able to find adequate replacements on a timely basis, or at all. We do not maintain key person life insurance policies on any of our employees.

  We may become subject to litigation.

  We may be forcedbecome subject to litigate, enforce, or defend our intellectual property rights, protect our trade secrets, or determine the validity and scope of other parties' proprietary rights. Such litigation, would be a drain on the financial and management resources of our companyincluding for possible product liability claims, which may affecthave a material adverse effect on our reputation, business, results from operations and business. Furthermore, because the content of most of our intellectual property concerns cannabis and other activities that are not legal in some state jurisdictions, we may face additional difficulties in defending our intellectual property rights.financial condition. We may become party to litigation from time to timebe named as a defendant in a lawsuit or regulatory action. We may also incur uninsured losses for liabilities, which arise in the ordinary course of business, or which are unforeseen, including, but not limited to, employment liability and business loss claims. Any such losses could adversely affecthave a material adverse effect on our business. Should any litigation in which we become involved in be determined against our company such a decision could adversely affect our ability to continue operating and the market price for our common shares and could use significant resources. Even if we are involved in litigation and wins, litigation can redirect significant company resources.business, results of operations, sales, cash flow or financial condition.

  5

  ---

  We may be subject to product recalls.

  Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labelling disclosure. If any of our products are recalled due to an alleged product defect or for any other reason, we could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. We may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Although we have detailed procedures in place for testing our products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if we are subject to a recall, the image of our company could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for our products and could have a material adverse effect on our results of operations and financial condition. Additionally, product recalls may lead to increased scrutiny of our operations by regulatory agencies, requiring further management attention, potential loss of applicable licenses and potential legal fees and other expenses.

  We could have issues with product liability due to the nature of the Company's products.

  As a processor and distributor of products designed to be ingested by humans, our company faceswe face an inherent risk of exposure to product liability claims, regulatory action, and litigation if ourits products are alleged to have caused significant loss or injury. In addition, the sale of our products involves the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Previously unknown adverse reactions resulting from human consumption of ourcannabis or other products alone or in combination with other medications or substances could occur. WeAs a processor and distributor and of such products or in its role as an investor in or service provider to an entity that is a manufacturer, distributor and/or retailer of adult-use of such products, we may be subject to various product liability claims, including, among others, that our productsthe product caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning possible side effects or interactions with other substances.

  A product liability claim or regulatory action against our companyus could result in increased costs, could adversely affect our company's reputation with clients and consumers generally, and could have a material adverse effect on our business, prospects,results of operations, financial condition and results of operations.or prospects. There can be no assurances that we will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtainmaintain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of our potential products or otherwise have a material adverse effect on our business, prospects,results of operations, financial condition or prospects.

  7

  ---

  Reputational risk and negative public opinion

  Damage to our reputation can result from the actual or perceived occurrence of any number of events, including any negative publicity, whether true or not. As a distributor of cannabis, which was previously a controlled substance in Canada, and as a holder of a Dealer's Licence permitting certain activities relating to substances currently classified as controlled substances, there is a risk that our business may attract negative publicity due to association of such products or substances with violence and criminal activities. There is also a risk that the actions of other licence holders, permitted retailers or other companies and service providers in the cannabis industry or entities authorized to deal with controlled substances, including those in the cannabis industry with whom we have or will enter into agreements with, may negatively affect the reputation of the industry as a whole and thereby negatively impact our reputation.

  The increased usage of social media and other web-based tools used to generate, publish and discuss user-generated content and to connect with other users has made it increasingly easier for individuals and groups to communicate and share negative opinions and views in regard to our activities and the industry in general, whether true or not. We do not ultimately have direct control over how we, the cannabis industry, or the controlled substance licensing regime is perceived by others. Reputational issues may result in decreased investor confidence, increased challenges in developing and maintaining community relations and present an impediment to our overall ability to advance our business strategy and realize on growth prospects, which could have a material adverse effect on our business, financial condition or results of operations.

  Industry volatility

  The cannabis industry and businesses ancillary to and directly involved with cannabis businesses are undergoing rapid growth and substantial change, which has resulted in an increase in competitors, consolidation and formation of strategic relationships. Acquisitions or other consolidating transactions could harm us in a number of ways, including by losing strategic partners if they are acquired by or enter into relationships with a competitor, losing customers, revenue and market share, or forcing us to expend greater resources to meet new or additional competitive threats, all of which could harm our operating results. As competitors enter the market and become increasingly sophisticated, competition in our industry may intensify and place downward pressure on retail prices for its products and services, which could negatively impact profitability.

  Although we currently has no intention of pursuing any activities under our Dealer's License, should we choose to engage in permitted activities as authorized by the Dealer's Licence in the future, we may face challenges related to the relatively new and rapidly evolving commercial environment relating to controlled substances, including managing a complex and highly regulated supply chain, developing and scaling operations, attracting and retaining talent necessary to perform the permitted activities under the conditions imposed by the Dealer's Licence and other regulatory restrictions, and the public perception of controlled substances. Since the industry for controlled substances is still in a very early stage in Canada, there are significant risks that any expenditures in developing a business that relies in part on commercialization of our Dealer's Licence will not result in profitable operations.

  We rely on third party relationships.

  We are dependent on several third-party relationships and their related costs, including raw materials and supplies related to their growing operations, as well as electricity, water and other utilities. Any significant interruption or negative change in the availability or economics of the supply chain from third-party relationships could materially impact our financial condition and operating results. Any inability to secure required supplies and services or to do so on appropriate terms could have a materially adverse impact on our business, financial condition and operating results.

  The third parties with which we do business may perceive that they are exposed to reputational risks as a result of our cannabis business activities, failure to establish or maintain business relationships could have a material adverse effect on our company.

  8

  ---

  Our advertising and promotional expenditures may not be effective or efficient.

  Our future growth and profitability will depend on the effectiveness and efficiency of advertising and promotional expenditures, including our ability to (i) create greater awareness of its products; (ii) determine the appropriate creative message and media mix for future advertising expenditures; and (iii) effectively manage advertising and promotional costs in order to maintain acceptable operating margins. There can be no assurance that advertising and promotional expenditures will result in revenues in the future or will generate awareness of our technologies or services. In addition, no assurance can be given that we will be able to manage our advertising and promotional expenditures on a cost-effective basis.

  6

  ---

  Being a public company requires significant obligations.

  Our Company incurs significant legal, accounting, insurance and other expenses as a result of being a public Company, which may negatively impact our performance and could cause our results of operations and financial condition to suffer. Compliance with applicable securities laws in Canada and the rules and policies of the Canadian Securities Exchange constitutes a significant expense, including legal and accounting costs, and makes some activities more time-consuming and costly. Reporting obligations as a public company and our anticipated growth may place a strain on our financial and management systems, processes and controls, as well as on personnel.

  Our company may rely onProprietary and intellectual property.property rights

  Our successability to compete may depend in part on the abilitysuperiority, uniqueness and value of any intellectual property and technology that we may develop. To the extent we are able to do so, to protect ideasany of our proprietary rights, we intend to rely on a combination of patent, trademark, copyright and technology. Eventrade secret laws, confidentiality agreements with our employees and third parties, and protective contractual provisions. Despite these efforts, any of the following occurrences may reduce the value of any of the Company's intellectual property:

  • Patents in the cannabis industry involve complex legal and scientific questions, and patent protection may not be available for some or any products; our applications for trademarks and copyrights relating to our business may not be granted, and, if we movegranted, may be challenged or invalidated;
  • Issued patents, trademarks and registered copyrights may not provide us with competitive advantages; our efforts to protect technology with trademarks, patents, copyrights or by other means, we are not assured that competitors will not develop similar technology, business methods or that they will be able to exercise their legal rights. Other countries may not protect intellectual property rights to the same standards as does Canada. Actions taken to protect or preserveour intellectual property rights may requirenot be effective in preventing misappropriation of any of our products or intellectual property;
  • Our efforts may not prevent the development and design by others of products or marketing strategies similar to or competitive with or superior to those we develop;
  • Another party may assert a blocking patent and we would need to either obtain a licence or design around the patent in order to continue to offer the contested feature or service in our products; or
  • The expiration of patent or other intellectual property protections for any assets owned by us could result in significant competition, potentially at any time and without notice, resulting in a significant reduction in sales. The effect of the loss of these protections on us and our financial results will depend, among other things, upon the nature of the market and other resources such that said actions havethe position of our products in the market from time to time, the growth of the market, the complexities and economics of manufacturing a meaningfullycompetitive product, and regulatory approval requirements, but the impact the ability to successfully grow our business.could be material and adverse.

  Fraudulent or illegal activity could occur within our company.

  Our Company is exposed to the risk that its employees, independent contractors and consultants may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to our company that violates: (i) government regulations; (ii) manufacturing standards; (iii) federal and provincial healthcare fraud and abuse laws and regulations; or (iv) laws that require the true, complete and accurate reporting of financial information or data. It is not always possible for our company to identify and deter misconduct by its employees and other third parties, and the precautions taken by our company to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting our company from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against our company, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of the Issuer's operations, any of which could have a material adverse effect on our business, financial condition and results of operations.

  9

  ---

  We cannot ensure product viability.

  If the products our company sells are not perceived to have the effects intended by the end user, our business may suffer. Many of our products contain innovative ingredients or combinations of ingredients. There is little long-term data with respect to efficacy, unknown side effects and/or interaction with individual human biochemistry. Moreover, there is little long-term data with respect to efficacy, unknown side effects and/or its interaction with individual animal biochemistry. As a result, our products could have certain side effects if not taken as directed or if taken by an end user that has certain known or unknown medical conditions.

  We rely on the success of our quality control systems.

  The quality and safety of our products are critical to the success of our business and operations. As such, it is imperative that our (and our service provider's) quality control systems operate effectively and successfully. Quality control systems can be negatively impacted by the design of the quality control systems, the quality training program, and adherence by employees to quality control guidelines. Although we strive to ensure that all of our service providers have implemented and adhere to high caliber quality control systems, any significant failure or deterioration of such quality control systems could have a material adverse effect on our business and operating results.

  7

  ---

  The cannabis industry and market are relatively new in Canada and this industry and market may not continue to exist or grow as anticipated.

  Our company operates its business in a relatively new industry and market. In addition to being subject to general business risks, we must continue to build brand awareness in this industry and market through significant investments in its strategy, its production capacity, quality assurance and compliance with regulations. In addition, there is no assurance that the industry and market will continue to exist and grow as currently estimated or anticipated or function and evolve in the manner consistent with management's expectations and assumptions. Any event or circumstance that adversely affects the cannabis industry and market could have a material adverse effect of our business, financial conditions and results of operations.

  The cannabis industry is difficult to quantify, and investors will be reliant on their own estimates of the accuracy of market data.

  Because the cannabis industry is in an emerging stage with uncertain boundaries, there is a lack of information about comparable companies available for potential investors to review in deciding about whether to invest in our company and, few, if any, established companies whose business model our company can follow or upon whose success our company can build. Accordingly, investors will have to rely on their own estimates in deciding about whether to invest in our company. There can be no assurance that our estimates are accurate or that the market size is sufficiently large for our business to grow as projected, which may negatively impact our financial results.

  The cannabis industry is very competitive.

  The marijuana production industry is competitive in all of its phases. We face strong competition from other companies in connection with such matters. Many of these companies have greater financial resources, operational experience and technical capabilities than us. As a result of this competition, we may be unable to maintain our operations or develop them as currently proposed, on terms we consider acceptable or at all. Consequently, the revenues, operations and financial condition of our company could be materially adversely affected.

  Because of early stage of the industry in which we operate, we may face additional competition from new entrants. If the number of users of marijuana in Canada increases, the demand for products will increase and we expect that competition will become more intense, as current and future competitors begin to offer an increasing number of diversified products. To remain competitive, we will require a continued high level of investment in research and development, marketing, sales and client support. We may not have sufficient resources to maintain research and development, marketing, sales and client support efforts on a competitive basis which could materially and adversely affect the business, financial condition and results of operations.

  Consolidation that may intensify competition.

  The cannabis industry is undergoing rapid growth and substantial change, which has resulted in an increase in competitors, consolidation and formation of strategic relationships. Acquisitions or other consolidating transactions could harm our company in a number of ways, including by losing strategic partners if they are acquired by or enter into relationships with a competitor, losing customers, revenue and market share, or forcing our company to expend greater resources to meet new or additional competitive threats, all of which could harm our operating results.

  10

  ---

  The processing of cannabis includes risks inherent in an agricultural business including the risk of crop loss, sudden changes in environmental conditions, equipment failure, product recalls and others.

  Our business will be subject to the risks inherent in the agricultural business, such as insects, plant diseases and similar agricultural risks. There can be no assurance that natural elements will not have a material adverse effect on our products.

  The cannabis industry could be subject to negative customer perception.

  We believe the cannabis industry is highly dependent upon consumer perception regarding the medical benefits, safety, efficacy and quality of the cannabis distributed for medical purposes to such consumers. Consumer perception can be significantly influenced by scientific research or findings, regulatory investigations, litigation, political statements both in Canada and in other countries, media attention and other publicity (whether or not accurate or with merit) regarding the consumption of cannabis products for medical or recreational purposes, including unexpected safety or efficacy concerns. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the medical cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for cannabis and the business, results of operations and financial condition of our company. Our dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity (whether or not accurate or with merit), could have an adverse effect on any demand for our services and products which could have a material adverse effect on our business, financial condition and results of operations. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of cannabis for medical purposes in general, or associating the consumption of cannabis with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers' failure to consume such products legally, appropriately or as directed.

  8

  ---

  The mushroom and mushroom-derived products could be subject to negative customer perception.

  We are dependent upon consumer perception of mushrooms and mushroom-derived products. The public may associate our mushrooms and mushroom-derived products with illegal psychoactive mushrooms, which are prohibited substances, which may negatively impact our future revenues once we obtain the necessary licensing.

  General healthcare regulation may affect our businesses.

  Healthcare service providers in Canada are subject to various governmental regulation and licensing requirements and, as a result, our businesses operate in an environment in which government regulations and funding play a key role. The level of government funding directly reflects government policy related to healthcare spending, and decisions can be made regarding such funding that are largely beyond the businesses' control. Any change in governmental regulation, delisting of services, and licensing requirements relating to healthcare services, or their interpretation and application, could adversely affect the business, financial condition and results of operations of these business units. In addition, we could incur significant costs in the course of complying with any changes in the regulatory regime. Non-compliance with any existing or proposed laws or regulations could result in audits, civil or regulatory proceedings, fines, penalties, injunctions, recalls or seizures, any of which could adversely affect the reputation, operations or financial performance of our company.

  We rely on physicians and other healthcare professionals.

  We rely on the availability of physicians and other healthcare professionals to provide services at our facilities. If physicians and other healthcare professionals were unable or unwilling to provide these services in the future due to any sort of reason, this would cause interruptions in our business until mitigated accordingly. As such, vacancies and disabilities relating to our current medical staff may cause interruptions in our business and result in lower revenues.

  11

  ---

  As we expand our operations, we may encounter difficulty in securing the necessary professional medical and skilled support staff to support our expanding operations. There is currently a shortage of certain medical physicians in Canada and this may affect our ability to hire physicians and other healthcare practitioners in adequate numbers to support our growth plans, which may adversely affect the business, financial condition and results of operations.

  Security breaches and other disruptions to our information technology networks and systems could substantially interfere with our operations and could compromise the confidentiality of our proprietary information.

  We rely upon information technology systems and networks, some of which are managed by third parties, to process, transmit and store electronic information, and to manage or support a variety of business processes and activities, including supply chain management, manufacturing, invoicing and collection of payments from our customers. Additionally, we collect and store sensitive data, including intellectual property, proprietary business information, the proprietary business information of our suppliers, as well as personally identifiable information of our employees, in data centers and on information technology systems. The secure operation of these information technology systems, and the processing and maintenance of this information, is critical to our business operations and strategy. Despite security measures and business continuity plans, our information technology systems and networks may be vulnerable to damage, disruptions or shutdowns due to attacks by hackers or breaches due to errors or malfeasance by employees, contractors and others who have access to our networks and systems, or other disruptions during the process of upgrading or replacing computer software or hardware, hardware failures, software errors, third-party service provider outages, power outages, computer viruses, telecommunication or utility failures or natural disasters or other catastrophic events. The occurrence of any of these events could compromise our systems and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability or regulatory penalties under laws protecting the privacy of personal information, disrupt operations and reduce the competitive advantage we hope to derive from our investment in technology. Our insurance coverage may not be available or adequate to cover all the costs related to significant security attacks or disruptions resulting from such attacks.

  9

  ---

  If consumers elect to produce cannabis for their own purposes under the cannabis regulations it could reduce the addressable market for our products.

  Under the Cannabis regulations, three options are available for an individual to obtain cannabis for medical purposes: (i) registering with a holder of a license to sell for medical purposes and purchasing products from that entity; (ii) register with Health Canada to produce a limited amount of cannabis for their own medical purposes; or (iii) designate someone else to produce cannabis for them. In addition, the Cannabis Act (as defined herein) permits households to grow a maximum of four cannabis plants for recreational purposes. Subject to further regulation by provincial and municipal governments it is possible that production of cannabis by consumers for medical or recreational purposes could significantly reduce the addressable market for our products and could have a material adverse effect on our business, financial condition or results of operations.

  We face competition from illicit dispensaries and the illicit market.

  We also face competition from illicit dispensaries and the illicit market more broadly. Participants in these markets are unlicensed and unregulated. They may be selling cannabis and cannabis products with higher concentrations of active ingredients and using classes of cannabis that are not yet regulated for sale in Canada. Various Canadian cities have seen an influx in the number of illicit dispensaries. Any inability or unwillingness of law enforcement authorities to enforce existing laws prohibiting the unlicensed cultivation and sale of cannabis and cannabis products could result in the perpetuation of the illicit market for cannabis and/or have a material adverse effect on the perception of cannabis use. Any or all these events could have a material adverse effect on our business, prospects, financial condition and results of operations.

  Risks Related to Our Company

  We may need to raise additional funds to support our business operations or to finance future acquisitions, including through the issuance of equity or debt securities, which could have a material adverse effect on our ability to grow our business.

  If we do not generate sufficient cash from operations or do not otherwise have sufficient cash and cash equivalents to support our business operations or to finance future acquisitions, we may need to raise additional capital through the issuance of debt or equity securities. We may not be able to raise cash in future financing on terms acceptable to us, or at all.

  12

  ---

  Financings, if available, may be on terms that are dilutive to our shareholders, and the prices at which new investors would be willing to purchase our securities may be lower than the current price of our common shares. The holders of new securities may also receive rights, preferences or privileges that are senior to those of existing holders of our common shares. If new sources of financing are required but are insufficient or unavailable, we would be required to modify our plans to the extent of available funding, which could harm our ability to grow our business.

  The report of our independent registered public accounting firm for the year ended December 31, 20212022 includes a "going concern" explanatory paragraph.

  The report of our independent registered public accounting firm on our consolidated financial statements as of and for the year ended December 31, 20212022 includes an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern. If we are unable to raise sufficient capital when needed, our business, financial condition and results of operations will be materially and adversely affected, and we will need to significantly modify our operational plans to continue as a going concern. If we are unable to continue as a going concern, we might have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our consolidated financial statements. The inclusion of a going concern explanatory paragraph by our auditors, our lack of cash resources and our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new capital or to enter into critical contractual relations with third parties.

  10

  ---

  We have no operating experience as a publicly traded company in the U.S.

  We have no operating experience as a publicly traded company in the U.S. Although the individuals who now constitute our management team have experience managing a publicly traded company, there is no assurance that the past experience of our management team will be sufficient to operate our company as a publicly traded company in the United States, including timely compliance with the disclosure requirements of the Securities and Exchange Commission. These requirements will place significant strain on our management team, infrastructure and other resources. In addition, our management team may not be able to successfully or efficiently manage our company as a U.S. public reporting company that is subject to significant regulatory oversight and reporting obligations.

  We lack operating history.

  We have only started to carry on our current business since 2019. We are therefore subject to many of the risks common to early-stage enterprises, including under-capitalization, cash shortages, limitations with respect to personnel, financial, and other resources. Our failure to meet any of these conditions could have a materially adverse effect on our company and may force us to reduce, curtail, or discontinue operations. There is no assurance that we will be successful in achieving a return on shareholders' investment and the likelihood of success must be considered in light of the early stage of operations. We may not successfully address all of the risks and uncertainties or successfully implement our existing and new products and services. If we fail to do so, it could materially harm our business and impair the value of our common shares, resulting in a loss to shareholders. Even if we accomplish these objectives, we may not generate the anticipated positive cash flows or profits. No assurance can be given that we can or will ever be successful in our operations and operate profitably.

  It may be difficult for non-Canadian investors to obtain and enforce judgments against us because of our Canadian incorporation and presence.

  We are a corporation existing under the laws of British Columbia, Canada. Some of our directors and officers, and the experts named in this annual report, are residents of Canada, and all or a substantial portion of their assets, and a substantial portion of our assets, are located outside the United States. Consequently, it may be difficult for holders of our common shares who reside in the United States to effect service within the United States upon our directors and officers who are not residents of the United States. It may also be difficult for holders of our common shares who reside in the United States to realize in the United States upon judgments of courts of the United States predicated upon our civil liability and the civil liability of our directors and officers under the United States federal securities laws. Investors should not assume that Canadian courts (i) would enforce judgments of United States courts obtained in actions against us or our directors or officers predicated upon the civil liability provisions of the United States federal securities laws or the securities or "blue sky" laws of any state within the United States or (ii) would enforce, in original actions, liabilities against us or our directors or officers predicated upon the United States federal securities laws or any such state securities or "blue sky" laws.

  13

  ---

  As a foreign private issuer, we are not subject to certain United States securities law disclosure requirements that apply to a domestic United States issuer, which may limit the information that would be publicly available to our shareholders.

  As a foreign private issuer, we will be exempt from certain rules under the Securities Exchange Act of 1934 that impose disclosure requirements as well as procedural requirements for proxy solicitations under Section 14 of the Securities Exchange Act of 1934. In addition, our officers, directors and principal shareholders will be exempt from the reporting and "short-swing" profit recovery provisions of Section 16 of the Securities Exchange Act of 1934. Moreover, we are not required to file periodic reports and financial statements with the Securities and Exchange Commission as frequently or as promptly as a company that files as a U.S. domestic issuer whose securities are registered under the Securities Exchange Act of 1934, nor are we generally required to comply with the Securities and Exchange Commission's Regulation FD, which restricts the selective disclosure of material non-public information. For as long as we are a "foreign private issuer" we intend to file our annual financial statements on Form 20-F and furnish our quarterly interim financial statements on Form 6-K to the Securities and Exchange Commission. However, the information we file or furnish is not the same as the information that is required in annual and quarterly reports on Form 10-K or Form 10-Q for U.S. domestic issuers. Accordingly, there may be less information publicly available concerning us than there is for a company that files as a U.S. domestic issuer.

  11

  ---

  Risks Related to Our Common Shares

  Because we can issue additional common shares, our shareholders may experience dilution in the future.

  We are authorized to issue an unlimited number of common shares without par value. Our board of directors has the authority to cause us to issue additional common shares without consent of our shareholders. The issuance of any such securities may result in a reduction of the book value or market price of our common shares. Given the fact that we have not achieved profitability or generated positive cash flow historically, and we operate in a capital-intensive industry with significant working capital requirements, we may be required to issue additional common equity or securities that are dilutive to existing common shares in the future in order to continue its operations. Our efforts to fund our intended business plan may result in dilution to existing shareholders. Further, any such issuances could result in a change of control or a reduction in the market price for our common shares.

  Volatility in our common share price may subject us to securities litigation.

  The market for our common shares may have, when compared to seasoned issuers, significant price volatility, and we expect that our share price may continue to be more volatile than that of a seasoned issuer for the foreseeable future. In the past, plaintiffs have often initiated securities class action litigation against a company following periods of volatility in the market price of its securities. We may, in the future, be the target of similar litigation. Securities litigation could result in substantial costs and liabilities and could divert management's attention and resources away from the day-to-day business operations.

  The market price of our common shares may be volatile and may fluctuate in a way that is disproportionate to our operating performance.

  Our common shares are listed on the Canadian Securities Exchange. Trading of shares on the Canadian Securities Exchange is often characterized by wide fluctuations in trading prices, due to many factors that may have little to do with our operations or business prospects.

  The volume of trading in our common shares has been low and the share price has fluctuated significantly. This volatility could depress the market price of our common shares for reasons unrelated to operating performance. The market price of our common shares could decline due to the impact of any of the following factors upon the market price of our common shares:

  •● sales or potential sales of substantial amounts of our common shares;

  •● announcements about us or about our competitors;

  •● litigation and other developments relating to our company or those of our suppliers or our competitors;

  •● conditions in the automobile industry;

  •● governmental regulation and legislation;

  14

  ---

  •● variations in our anticipated or actual operating results;

  •● change in securities analysts' estimates of our performance, or our failure to meet analysts' expectations;

  •● change in general economic conditions or trends;

  •● changes in capital market conditions or in the level of interest rates; and

  •● investor perception of our industry or our prospects.

  Many of these factors are beyond our control. The stock markets in general, and the market price of shares of companies in the cannabis industries, have historically experienced extreme price and volume fluctuations. These fluctuations often have been unrelated or disproportionate to the operating performance of these companies. These broad market and industry factors could reduce the market price of our common shares, regardless of our actual operating performance.

  A prolonged and substantial decline in the price of our common shares could affect our ability to raise further working capital, thereby adversely impacting our ability to continue operations.

  A prolonged and substantial decline in the price of our common shares could result in a reduction in the liquidity of our common shares and a reduction in our ability to raise capital. Because we plan to acquire a significant portion of the funds, we need in order to conduct our planned operations through the sale of equity securities, a decline in the price of our common shares could be detrimental to our liquidity and our operations because the decline may cause investors not to choose to invest in our shares. If we are unable to raise the funds, we require for all our planned operations and to meet our existing and future financial obligations, we may be forced to reallocate funds from other planned uses and may suffer a significant negative effect on our business plan and operations, including our ability to develop new products and continue our current operations. As a result, our business may suffer, and we may go out of business.

  12

  ---

  Because we do not intend to pay any cash dividends on our common shares in the near future, our shareholders will not be able to receive a return on their shares unless they sell them.

  We intend to retain any future earnings to finance the development and expansion of our business. We do not anticipate paying any cash dividends on our common shares in the near future. The declaration, payment and amount of any future dividends will be made at the discretion of our board of directors, and will depend upon, among other things, the results of operations, cash flows and financial condition, operating and capital requirements, and other factors as the board of directors considers relevant. There is no assurance that future dividends will be paid, and if dividends are paid, there is no assurance with respect to the amount of any such dividend. Unless we pay dividends, our shareholders will not be able to receive a return on their shares unless they sell them.

  15

  ---

  Our common shares are subject to penny stock rules. Trading of our common shares may be restricted by the Securities and Exchange Commission's penny stock regulations, which may limit a shareholder's ability to buy and sell our common shares.

  Our common shares are penny stock. The Securities and Exchange Commission has adopted Rule 15g-9 which generally defines "penny stock" to be any equity security that has a market price (as defined) less than US$5.00 per share or an exercise price of less than US$5.00 per share, subject to certain exceptions. Our securities are covered by the penny stock rules, which impose additional sales practice requirements on broker-dealers who sell to persons other than established customers and "accredited investors". The term "accredited investor" refers generally to institutions with assets in excess of US$5,000,000 or individuals with a net worth in excess of US$1,000,000 or annual income exceeding US$200,000 or US$300,000 jointly with their spouse. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared by the Securities and Exchange Commission which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction and monthly account statements showing the market value of each penny stock held in the customer's account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer's confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the common shares that are subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to trade our securities. We believe that the penny stock rules discourage investor interest in, and limit the marketability of, our common shares.

  The Financial Industry Regulatory Authority sales practice requirements may also limit a shareholder's ability to buy and sell our common shares.

  In addition to the "penny stock" rules promulgated by the Securities and Exchange Commission, the Financial Industry Regulatory Authority or FINRA has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer's financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common shares, which may limit your ability to buy and sell our shares.

  We may be classified as a "passive foreign investment company," which may have adverse U.S. federal income tax consequences for U.S. shareholders.

  Generally, for any taxable year in which 75% or more of our gross income is passive income, or at least 50% of the average quarterly value of our assets (which may be determined in part by the market value of our common shares, which is subject to change) are held for the production of, or produce, passive income, we would be characterized as a passive foreign investment company ("PFIC") for U.S. federal income tax purposes. Our status as a PFIC is a fact-intensive determination made on an annual basis, and we cannot provide any assurance regarding our PFIC status for the taxable year ending December 31, 20212022 or for future taxable years.

  13

  ---

  If we are a PFIC for any year during a non-corporate U.S. shareholder's holding period of our common shares, then such non-corporate U.S. shareholder generally will be required to treat any gain realized upon a disposition of our common shares, or any so-called "excess distribution" received on our common shares, as ordinary income, rather than as capital gain, and the preferential tax rate applicable to dividends received on our common shares would not be available. Interest charges would also be added to the taxes on gains and distributions realized by all U.S. holders.

  A U.S. shareholder may avoid these adverse tax consequences by making a timely and effective "qualified electing fund" election ("QEF election"). A U.S. shareholder who makes a QEF election generally must report, on a current basis, its share of our ordinary earnings and net capital gains, whether or not we distribute any amounts to our shareholders. The QEF election is available only if our company characterized as a PFIC provides a U.S. shareholder with certain information regarding its earnings and capital gains as required under applicable U.S. Treasury regulations. In the event we become a PFIC, U.S. Holders should be aware that we might not satisfy the recordkeeping requirements that apply to a QEF or supply U.S. Holders with information such U.S. Holders require to report under the QEF rules in the event that our company is a PFIC for any tax year.

  16

  ---

  A U.S. shareholder may also mitigate the adverse tax consequences by timely making a mark-to-market election. A U.S. shareholder who makes the mark-to-market election generally must include as ordinary income each year the increase in the fair market value of the common shares and deduct from gross income the decrease in the value of such shares during each of its taxable years. A mark-to-market election may be made and maintained only if our common shares are regularly traded on a qualified exchange. Whether our common shares are regularly traded on a qualified exchange is an annual determination based on facts that, in part, are beyond our control. Accordingly, a U.S. shareholder might not be eligible to make a mark-to-market election to mitigate the adverse tax consequences if we are characterized as a PFIC.

  Each U.S. shareholder should consult their own tax advisors with respect to the possibility of making these elections and the U.S. federal income tax consequences of the acquisition, ownership and disposition of our common shares. This paragraph is qualified in its entirety by the discussion in the section of this annual report entitled "Certain Material United States Federal Income Tax Considerations." In addition, our PFIC status may deter certain U.S. investors from purchasing our common shares, which could have an adverse impact on the market price of our common shares.

  Item 4. Information on the Company

  A. History and Development of the Company

  We are a corporation incorporated under the Business Corporations Act (British Columbia) in British Columbia, Canada under the name "Adastra Holdings Ltd." with an authorized share structure of unlimited number of common shares without par value. Our principal place of business is located at 5451 - 275 Street, Langley, British Columbia V4W 3X8, Canada and our telephone number is (778) 715-5011. Our registered and records office is located at 800900 - 885 West Georgia Street, Vancouver, British Columbia V6C 3H1, Canada.

  We are an extraction and processing solutions company. Our mission is to develop and deploy large-scale cannabis and hemp extraction technologies and provide turn-key processing solutions to help licensed standard and micro-cultivators maximize the value of every harvest. We are also applying for a dealers licence for mushroom and mushroom-derived products in preparation for licencing of psychedelics in Canada, and operate a research-based multidisciplinary centre with physicians and healthcare professionals providing medical cannabis therapies.

  History of the Company

  Our Company was incorporated under the laws of the province of British Columbia on October 14, 1987. On December 19, 2019, our company changed its name to "Adastra Labs Holdings Ltd." from "Arrowstar Resources Ltd." (our company prior to this change of name, "Arrowstar"). On March 19, 2021, our company changed its name to "Phyto Extractions Inc." from "Adastra Labs Holdings Ltd.". On April 9, 2021, our company completed a consolidation of its common shares (on the basis of one (1) post consolidated common share for every three (3) pre-consolidation shares). On September 1, 2021, our company changed its name to "Adastra Holdings Ltd." from "Phyto Extractions Inc.".

  14

  ---

  On December 20, 2019, Arrowstar acquired all of the issued and outstanding common shares of Adastra Labs Holdings (2019) Ltd. ("Adastra"), a private British Columbia cannabis extraction and processing solutions company incorporated on June 18, 2018. The transaction was accounted for as a reverse acquisition, with Adastra being identified as the accounting acquirer and the net assets of Arrowstar at the date of the transaction are deemed to have been acquired by Adastra. At the time of the transaction, we changed our financial year end from April 30 to December 31.

  On August 31, 2021, we acquired all of the issued and outstanding common shares of 1225140 B.C. Ltd., doing business as PerceiveMD, ("PerceiveMD"), pursuant to the terms of a share purchase agreement dated August 10, 2021. PerceiveMD owns a private British Columbia research-based multidisciplinary center for medical cannabis and other therapies. We intend to employ physicians and other healthcare professionals at our clinics related to the operations of PerceiveMD will provide consultations to patients regarding the benefits of using cannabis-based products. Patients will be seen by a licensed physician and prescribed cannabis-based products.

  17

  ---

  At this time, we cannot fulfill any prescriptions ourselves as we do not hold the medical licence required from Health Canada and the College of Physicians and Surgeons. Instead, the prescription will be fulfilled by a licensed producer. We are preparing documents for the medical licence application, which will be submitted shortly, and we expect this to be approved in approximately three months.  We are confident that our application will be successful, however, if, in the unlikely event, we are unsuccessful in this application we will continue to operate under our current model with prescriptions fulfilled by a licensed producer.

  On September 17, 2021, we acquired all of the issued and outstanding common shares of 1204581 B.C. Ltd. ("1204581BC") pursuant to the terms of a share purchase agreement dated September 15, 2021. 1204581BC is the owner of intellectual property rights for the Phyto Extractions Brand.

  Development of the Company

  On October 18, 2018, Adastra submitted applications with Health Canada for the licenses under "An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts" (the "Cannabis Act"), which licenses will designate Adastra and Chemia Analytics Inc. ("Chemia"), a wholly owned subsidiary of Adastra, as a licensed processor and a licensed cannabis tester, respectively.

  On January 9, 2019, Adastra entered into a lease agreement with 1178562 B.C. Ltd., the holder of the property. On June 12, 2019, Adastra acquired all of the shares of 1178562 B.C. Ltd.

  In mid-February 2019, Adastra finalized its plans for the retrofit of the building located at 5451 275th Street, Langley, British Columbia V4W 3X8, Canada (the "Facility"). In late February/early March 2019, Adastra submitted materials to the Township of Langley for re-zoning and commenced the retrofit of the Facility. On March 15, 2019, Adastra completed demolition and re-insulation of the Facility. On April 14, 2019, Adastra received unanimous Township of Langley Council approval to proceed with rezoning of the Facility. On May 10, 2019, Adastra received a status letter from Health Canada advising that there are no critical concerns at this time. On May 27, 2019, Adastra received final approval from the Township of Langley for re-zoning of the Facility. On June 10, 2019, Adastra had commenced the post-demolition portion of the retrofit of the Facility. In late November 2019, Adastra completed the retrofit of the Facility and on December 2, 2019, Adastra submitted its evidence package for its Cannabis (processing, sales) license application to Health Canada.

  During April 2021, the Company completed the installation of its hydrocarbon extraction line, allowing it to produce Shatter products for the Canadian market. This high-performance hydrocarbon extractor allows the Company to process over 400 kg per day of dried cannabis into a variety of shatter cannabis products.

  On February 9, 2023, the Company announced that it had terminated a legacy supply agreement for the Company's Phyto Extractions Brand. The household brand for legacy cannabis concentrates was 100% acquired as part pf the acquisition of Phyto Brandco. A legacy licence agreement remained in place following the acquisition, whereby Phyto utilized a third party's licensing status with Health Canada to exclusively package and sell its popular Phyto branded cannabis consumer packaged products on its behalf, in consideration for payment of royalties back to Phyto (the "Phyto Licence Agreement"). On August 30, 2022, Adastra announced it had entered into an agreement with the third party, whereby Adastra had the right and option to terminate the Phyto Licence Agreement subject to certain conditions which have now been met.

  Licences of the Company

  On October 25,18, 2018, Adastra submitted applications with Health Canada for the licenses under "An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts" (the "Cannabis Act"), which licenses will designate Adastra and Chemia Analytics Inc. ("Chemia"), a wholly owned subsidiary of Adastra, as a licensed processor and a licensed cannabis tester, respectively.

  On October 19, 2019, Chemia received itsa licence from Health Canada (the "Analytical Testing Licence") to conduct analytical testing license from Health Canada. on cannabis at its Facility.

  On March 16,13, 2020, Health Canada issuedthe Company, through its wholly owned subsidiary, Adastra Labs Inc. ("ALI"), received a Standard Processing License onlicence (the "Processing Licence") for the Facility to Adastra. Health Canada issued an Analytical Testing License to our facility owned by Chemia. The license became effective March 17, 2020. WeFacility.

  On April 16, 2021, the Company received an amendment to our Standard Processing License authorizing the sale of cannabis extract, cannabis edibles and cannabis topicals on March 13, 2021, and our research licenseits Analytical Testing Licence allowing for organoleptic testing on April 16, 2021.of its products.

  In August 2021, the Company submitted a further sales licence amendment for dried flower and a controlled substance dealer's licence for cannabis products. On December 16, 2021, the Company received its Flower Sales LicenseLicence from Health Canada ("Flower License"Licence"), this will allowthat permits the Company to sell dried cannabis flower products provincially and territorially in Canada.

  On March 23,August 12, 2022, the Company submittedreceived its application for a Controlled Substances Dealer's License (the "Dealer's License") which will allow the Company to procure controlled substances, including synthesis, propagation, cultivation, and harvesting of psychedelic mushrooms for Psilocybin extraction, research and manufacture controlled substances such as Psilocybin and Psilocin and business-to-business sale of controlled substances, including by export. The Dealer's License application was originally filed in September, 2021 with a Health Canada audit performed on March 9, 2022. The Company responded to Health Canada's request for more information and successfully submitted its Dealer's License application on March 23, 2022. Unless Health Canada comes back with an additional request for information, the Company expects the Dealer's License to be received in May 2022.

  15

  ---

  On April 11 2022 the Company submitted its application for a medical sales licenselicence (the "Medical Sales License"Licence") which will allowthat permits the Company to sell cannabis extracts to medical cannabis patients and licensedlicenced health practitioners and to develop products classed as cannabis extracts such as tinctures, oils, capsules, soft gels and sprays.  The Company expects this license to be received in 6 to 8 weeks following the submission on April 11, 2022.

  On August 24, 2022, the Company received its Controlled Substances Dealer's Licence (the "Dealer's Licence") which allows the Company to procure and process controlled substances, including synthesis, propagation, cultivation, and harvesting of mushrooms for controlled substance extraction, research and manufacture controlled substances and business-to-business sale of controlled substances, including by export. The Dealer's License does not permit the Company to sell controlled substances to the public. For such substances, the Company is only permitted to sell to other licensed dealers who have such substances listed on their license including pharmacists, practitioners, hospitals, or the holder of a Section 56(1) exemption for research purposes under the Controlled Drugs and Substances Act (CDSA).

  18

  ---

  On February 22 and March 3, 2023, the Company announced that its wholly-owned subsidiary, ALI, received approval from Health Canada on February 17, 2023, for its amendment of the Dealer's License to include the following regulated activities: possession, production, assembling, sale/provision and sending, transportation and delivery of certain controlled substances. ALI may only produce certain specified amounts depending upon the compound in particular, ranging from 250 grams to 1,000 grams, in 2023. The Dealer's Licence does not permit ALI to sell such controlled substances to the general public. Under the Dealer's Licence, ALI is only permitted to sell to other licenced dealers who have such substances listed on their licence including pharmacists, practitioners, hospitals or the holder of a section 56(1) exemption for research purposes under the CDSA.

  The Company is not currently undertaking any activities with controlled substances under the Dealer's Licence, including selling to other licenced dealers, business-to-business sale, or export, and does not intend to undertake any activities relating to controlled substances for the foreseeable future. As such, the Company has no plan to use or rely upon the Dealer's Licence as at the date of this Form 20-F annual report. At this time, and for the foreseeable future, the Company solely intends to pursue its cannabis extracts business.

  Below is a chart containing all of the Company's current licences, the activities permitted under each licence, any restrictions on the use of each licence, and expiry dates:

  Licence	Permitted Activities	Restrictions	Expiry Date
  Standard Processing (Health Canada Licence No. LIC-SRIM66H586-2023)	To possess cannabis To produce cannabis, other than obtain it by cultivating, propagating or harvesting it To sell cannabis in accordance with subsection 17(5) of the Cannabis Regulations	The licence holder must meet the requirements set out in the Health Canada document entitled "Mandatory cannabis testing for pesticide active ingredients - Requirements" The only cannabis products that the licence holder may sell or distribute to a holder of (i) a licence for sale, and (ii) a person that is authorized under a provincial Act referred to in subsection 69(1) of the Act to sell cannabis, are as follows: cannabis plants, cannabis plant seeds, dried cannabis, fresh cannabis, cannabis topicals, cannabis extracts, and edible cannabis. The only cannabis products that the licence holder may send or deliver to the purchaser at the request of (i) a holder of a licence for sale, and (ii) a person that is authorized under a provincial Act referred to in subsection 69(1) of the Act to sell cannabis, are as follows: cannabis plants; cannabis plant seeds; dried cannabis; fresh cannabis; cannabis topicals; cannabis extracts; and edible cannabis.	February 16, 2028
  Sale for Medical Purposes (Health Canada Licence No. LIC-SRIM66H586-2023)	To possess cannabis To sell cannabis products in accordance with section 27 and Part 14, Division 1 of the Cannabis Regulations	N/A	February 16, 2028

  19

  ---

  Licence	Permitted Activities	Restrictions	Expiry Date
  Analytical Testing (Health Canada Licence No. LIC-WOUX7802CE-2022)   [issued to Chemia Analytics Inc.]	To possess cannabis for the purpose of testing To obtain cannabis by altering its chemical or physical properties by any means for the purpose of testing	Any pesticide testing activities conducted under the scope of Health Canada's "Mandatory cannabis testing for pesticide active ingredients-Requirements" must meet the requirements set out in that document	August 24, 2027
  Research (Health Canada Licence No. LIC-ZIDPSA6BYY-2021-2)	To possess cannabis for the purpose of research To produce cannabis for the purpose of research	This licence is restricted, in addition to all other applicable conditions, in that all research conducted under this licence is based on the Research Protocol "Organoleptic - Sensory - Taste Testing of Cannabis Products" provided to Health Canada on January 26, 2021 The maximum quantity of cannabis to be stored for the purpose of research at the address indicated on this licence is: 11 kg of dried cannabis (or equivalent) at any given time The researcher may only possess and produce cannabis if such possession and production is to use in accordance with the research protocol submitted With respect to research involving the administration or distribution of cannabis to human research subjects for assessments of taste, sight, smell or touch of cannabis, in addition to any other conditions listed in this licence, the researcher must meet the requirements set out in the document entitled Appendix: Additional conditions for licenced researchers administering or distributing cannabis to human research subjects using cannabis obtained from a holder of a licence for processing in the final form of cannabis All record keeping requirements pertaining to this research licence must be met in accordance with Part 11 of the Cannabis Regulations At the end of the research, all cannabis must be destroyed in accordance with s.43 of the Cannabis Regulations unless distributed in a manner authorized by the Cannabis Regulations	April 16, 2026

  ---

  Licence	Permitted Activities	Restrictions	Expiry Date
  Dealer's Licence (Health Canada Licence No. 6-1360)	Possession, production, assembling, sale/provision, sending, transportation and delivery of controlled substances, including their salts as listed in the Regulations and specified by this licence List of controlled substances, including their salts, that are specified in the licence in certain compounds up to 1000g), and certain other compounds (up to 250g).	Under the Dealer's Licence, holder is only permitted to sell to other licenced dealers who have such substances listed on their licence including pharmacists, practitioners, hospitals or the holder of a section 56(1) exemption for research purposes under the CDSA The controlled substance may only be sold or provided to the holder of a dealer's licence for controlled substances or the holder of an authorization issued under subsection J.01.059(4) of Part J of the Food and Drug Regulations Any sale or provision of the controlled substance or controlled substance-containing fungi, other than to another licenced dealer, must be approved in writing by Health Canada prior to the sale or provision taking place Sale or provision to the holder of a Controlled Drugs and Substances Act subsection 56(1) exemption is strictly prohibited The sale or provision of the controlled substance to a licenced dealer or authorization holder may only be for clinical testing in the institution by qualified investigators for the purpose of determining the hazards and efficacy of the drug; or laboratory research in the institution by qualified investigators; or destruction Room 121 is a restricted room at the Facility Access to room 121 is restricted to the following individuals: designated personnel for this licence, as per the most recent list of approved personnel issued by Health Canada; or employees conducting activities under this licence and under the supervision of designated personnel for this licence This licence does not authorize the cultivation of fungi or plants containing controlled substance(s)	July 31, 2023

  Takeover Offers

  We are not aware of any indication of any public takeover offers by third parties in respect of our common shares during our last and current financial years.

  The Securities and Exchange Commission maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the Securities and Exchange Commission. Such filings are available to the public over the internet at the Securities and Exchange Commission's website at http://www.sec.gov.

  B. Business Overview

  We are an integrated Canadian cannabis company focused on extraction and associated analytical testing. We, through one of our wholly owned subsidiaries, have a license to produce cannabis extracts under the Cannabis Act (LIC-SRIM66H586-2020).Act. In addition, we, through one of our wholly owned subsidiaries, have been granted a license by Health Canada to conduct analytical testing for the cannabis industry (LIC-WOUX7802CE-2019). Theindustry. We have been granted certain other licenses by Health Canada as described under Licenses of the Company in the section entitled History of the Development of Our Business.

  21

  ---

  Our Facility is a purpose-built facility with a view to be in compliance with European Union ("EU") Good Manufacturing Practices ("GMP") standards, which will allow us, subject to obtaining any necessary permits to export the products from the Facility to international destinations where cannabis is nationally legal for medical or adult usage purposes. We intend to export only to authorized recipients / countries - initially the EU for medical cannabis extracts once GMP accredited. There will be no US exports unless there is a change in US federal law. The Facility was completed in the quarter ended March 31, 2020 and became operational in April 2020.

  Cannabis

  The terms cannabis and marijuana are used interchangeably in Canada. The two main types of cannabis/marijuana are the Sativa and Indica plants, with hybrid strains being created when the genetics of each are crossed. Within each type of cannabis, there are hundreds of different phytochemical compounds, including many different cannabinoids (the most common being detla-9-tetrahydrocannabinol ("THC"), which is the psychoactive ingredient, and cannabidiol ("CBD"), which is responsible for many of the non-psychoactive effects of medical marijuana.

  Cannabis can be used for either recreational or medicinal purposes and typically comes in the form of dried plant, powder form, resin or oil. Cannabis for medical use was legalized in Canada in 2001. Cannabis for recreational use was legalized in Canada in 2018.

  Regulatory Framework

  Cannabis was legalized in Canada for medicinal use in 2001 and has been a commonly prescribed medication since then. The production, distribution and sale of medicinal and adult-use cannabis is tightly controlled by the Canadian federal government. In 2013, Health Canada introduced the commercial cannabis licensed producer program under the Marijuana for Medical Purposes Regulations ("MMPR") program. In 2015, the Supreme Court of Canada found certain elements of the MMPR unconstitutional which led to the development of the "ACMPR" (Access to Cannabis for Medical Purposes Regulations), specifically medical cannabis patients having the right to use oils and derivative forms of cannabis. In August 2016, the MMPR was replaced by the ACMPR. The ACMPR program as it relates to commercial production is very similar to the MMPR.

  The Canadian federal Cannabis Act came into force on October 17, 2018, to create a new legal regime for non-medicinal, or recreational, cannabis and to continue the legal regime for medicinal cannabis. Medicinal cannabis continues to be subject to different rules than recreational cannabis. The production and sale of medicinal cannabis is governed strictly by the federal government, whereas the regime for recreational cannabis is created by federal, provincial and municipal regulations.

  16

  ---

  The federal government regulates cannabis through the Cannabis Act, and governs the rules and regulations regarding:

  •● Minimum legal age requirement for recreational cannabis customers.

  •● Types of cannabis products available for sale. The sale of certain amounts of dried cannabis, fresh cannabis, cannabis oils, cannabis plants and cannabis plant seeds are legal as of October 17, 2018. Edibles containing cannabis and cannabis concentrates became legally available for sale October 17, 2019.

  •● Packaging and labelling requirements for products.

  •● Restrictions on promotional activities, displays and dispensing.

  •● Legalization of possession in public of 30 grams or less of dried cannabis, or the equivalent amount of other legal types of cannabis products, for someone 18 years of age or older, while maintaining a criminal offence for possession of more than that amount.

  •● Legalization of growing up to four cannabis plants in a private residence, while maintaining offences for having more than that or having them in a public place.

  •● Creating a licensing regime and requirements for the commercial production of cannabis and its wholesale sale to provincial and territorial distributors.

  •● Authorizing the provinces and territories to each legislate to create a new regulatory regime in their respective jurisdictions for the distribution and sale of recreational cannabis to persons 18 years of age or older.

  •● Maintaining offences for production, distribution or selling of cannabis outside of the newly regulated cannabis industry (with some exceptions).

  •● Continuing the separate legal regime for growing and selling medicinal cannabis to medical patients.

  22

  ---

  Under the regime created by the Cannabis Act, the federal government licenses and regulates the growing, processing and production of cannabis products for commercial purposes, and each province and territory controls the distribution and sale of recreational cannabis in their jurisdiction. Each jurisdiction is adopting unique legislation to address these issues. Only cannabis products that are grown or produced by a federally licensed producer may be sold or purchased in the provinces and territories. The distribution model of each province will not adversely affect our company as a business-to-business provider.

  Each provincial or territorial government is responsible for its own regime for the distribution and sale of recreational cannabis in its jurisdiction. For example, in Saskatchewan, retail cannabis is sold by private retailers, in Quebec, by a government-operated public entity and, in British Columbia, by a combination of public and private retailers. Each province and territory also has the power to add, within its jurisdiction, more restrictive regulations from some of those in the federal legislation, including:

  •● Lowering the limit of cannabis permissible for personal recreational possession and consumption.

  •● Adding any rules and regulations to those for home grown recreational cannabis.

  •● Restricting the consumption of recreational cannabis in public spaces.

  •● Raising the minimum age for possession and consumption of cannabis.

  Municipalities have the powers given to them by provincial statutes. Municipalities are given some authority over land use regulation and have the power to prohibit and regulate certain uses through zoning by-laws. Generally, the use carried out at any commercial real property must fit within the applicable zoning by-laws or the municipality can stop or prevent the use from being carried out on that real property.

  Psychedelics are Schedule III substances under the Controlled Drugs and Substances Act for which the extraction of raw materials from, or involvement in production activities are regulated federally in Canada. In order to develop our business and undertake research and development, the Company is applying for a dealer license for psychedelics which, if obtained, will allow the Company to possess and formulate psychedelics. At present a dealer license holder can only trade with another individual who has the same license. Their activities are limited in trade and they cannot provide substances to individuals or companies as Health Canada has yet to approve psychedelics as a drug and it is currently illegal to possess psychedelics in Canada without a dealer license or other exemption. While we anticipate being successful in this application, there is no guarantee that we will obtain a dealer license to possess and formulate psychedelics. If we are successful in this application there remain uncertainties with respect to how government regulations will impact our business with respect to psychedelics.  The Company is in the process of assessing this impact. 

  17

  ---

  Current Status of Cannabis License Applications

  On May 5, 2023, Adastra submitted an application with the British Columbia Liquor and Cannabis Regulation Branch (LCRB) for a Cannabis Marketing License which allows marketers to promote the products of licensed federal cannabis producers to licensed cannabis retail stores and people over 19-years-old.

  The ACMPR was repealed when the Cannabis Act and the cannabis regulations came into effect on October 17, 2018. Under the new regime, when an applicant applies for a license there are four sub-categories to choose from:

  (a)Cannabis (cultivation, processing, sales);

  (b)Industrial Hemp;

  (c)Research; and

  (d)Analytical Testing.

  On October 18, 2018, Adastra submitted two applications with Health Canada for the licences under the Cannabis Act. This included an application for Adastra under the first category: Cannabis (cultivation, processing, sales) and an application for Chemia under the fourth category: (Analytical Testing). The Cannabis license that Adastra has applied for permit it to process and sell its products for either medical or recreational use. Chemia has been granted an Analytical Testing license by Health Canada effective October 25, 2019.  Adastra has been granted a Standard Processing License for production of cannabis extracts and sale of cannabis extracts to other Health Canada licensed companies) by Health Canada on March 13, 2020. Adastra has also been granted a Research License for organoleptic testing on April 16, 2021 from Health Canada.

  On December 16, 2021 the Company received its Flower Sales License from Health Canada ("Flower License"), this will allow the Company to sell dried cannabis flower products provincially and territorially in Canada.

  On April 11 2022 the Company submitted its application for a medical sales license (the "Medical Sales License") which will allow the Company to sell cannabis extracts to medical cannabis patients and licensed health practitioners and to develop products classed as cannabis extracts such as tinctures, oils, capsules, soft gels and sprays.  The Company expects this license to be received in 6 to 8 weeks following the submission on April 11, 2022.

  Our business depends on these threeits licenses and the loss of any one of them could have a material adverse effect on our business, results of operations and financial condition.

  Other Intellectual Property

  Pursuant to the acqusitionacquisition of 1204581BC the Company becamesbecame the owner of intellectual property rights for the Phyto Extractions Brand. The Company benefits from the brand awareness of the Phyto Extractions Brand to market both the current and potential future cannabis products.

  Facility

  On January 9, 2019, Adastra entered into a lease agreement with 1178562 B.C. Ltd., the holder of the property. Adastra has subsequently acquired all the common shares of 1178562 B.C. Ltd. The Facility is a 13,035 square foot building that was a former food manufacturing facility.

  1823

  ---

  Existing Facility Floorplan 13,035 sq. ft.

  

  The site was chosen with two important considerations in mind. First, the current design and use of the facility as a food manufacturing facility for 20 years ensures the infrastructure and familiarity of Health Canada regulators with the Facility are optimal for conversion to a GMP cannabis extraction and analytical testing operation. Second, the strategic location in the Lower Mainland of British Columbia allows Adastra and Chemia to service licensed producers and other cannabis industry operations with easy access.

  1924

  ---

  Proposed Facility Layout

  

  The Facility modifications are under design with a cross-functional team of cannabis industry consultants, equipment manufacturer design input, and construction and design contractors.

  2025

  ---

  Revised Floorplan

  

  Adastra and Chemia operate together at the Facility. Some portions of the Facility restrict access to Adastra or Chemia.

  We completed the renovation of the Facility during the quarter ended March 31, 2020 at a cost of $3,900,000.

  Extraction Equipment

  Adastra has selected Supercritical CO2 extraction equipment and has agreed to purchase an extraction system that includes the ExtraktLAB Series 140 CO2 extractor along with the necessary additional equipment and software required for its operation of the extractor for an agreed price of $756,900. These units have a capacity of processing 422 pounds of cannabis biomass per day with a crude cannabis oil yield of 11-19% based on the cannabis flower/trim combinations intended to be used as extraction biomass.

  2126

  ---

  We purchased and setup extraction, processing and testing equipment during the quarter ended March 31, 2020. We fully outfitted our centralized facility with equipment necessary to process cannabis at cost of $1,200,000.

  The ability to further process cannabis crude to distillate, a high potency cannabinoid product containing over 90% active ingredient was contingent on the purchase of distillation equipment. Adastra purchased two Germany made wiped-film short path distillation units, one for $362,950 from Root Sciences, paid in cash, and the other for $386,215 from CapSure Consulting Ltd., paid through the issuance of 471,685 shares at a fair value price of $0.84 per common share. The common shares issued were subject to a hold period of four months and one day from the date of issuance. Together these machines refine cannabis crude a rate of 6.61 lbs per minute and provide a bulk salable product or the input into consumer-packaged goods such as edibles, topical and vaporizer cartridges.

  Adastra also invested in two RoboCap RL-300s from ATG Pharma. Both filling machines were purchased for a total of $114,470 and commissioned in June 2020. These assets fill vaporizer cartridges, small bottles and candy molds. Together the two machines are capable of producing 45,000 vaporizer cartridges per day.

  Adastra expanded its operational capabilities in October 2020 through the purchase of a high-capacity EV-Mass 30 Cryogenic Ethanol Extraction system from Evolved Extractions for $760,440. This extraction system can process more than 900 lbs of cannabis biomass per day with a yield of 11-19% to crude with fewer post-processing steps than Supercritical CO2 extraction.

  Beginning in December 2020 Adastra began to retrofit the Facility to allow for the use of butane and propane. This construction, completed in February 2021, permitted the installation of MeP70XT Hydrocarbon Extractor from ExtractionTek Solutions LLC. This extractor and ancillary equipment was purchased for a total of $284,010 and has allowed for the production of rare, high margin Butane Hash Oil products including shatter, waxes, crumble, live resin, diamonds & sauce and more. This extractor can extract over 400 kgs of cannabis biomass per day.

  Laboratory Equipment

  Chemia will be required to perform all cannabis testing specified in the Cannabis Act regulations. Chemia expects to require the following specific equipment in addition to other miscellaneous equipment:

  • 1x LCMS-8060 Triple Quadrupole Detector Package

  • 1x GCMS-TQ8050 w/EI ion source Smart PackGE

  • 1x ICPMS-2030 Mass Spectrometer

  • 1x Multiwave GO Microwave Digestion System

  • 1x Cannabis Analyzer Base Package: LC-2030C

  Operations

  Principal Products

  We are a health and wellness company focused on the processing of cannabis and cannabis analytical testing. We provide processing solutions to licensed cultivators of cannabis and hemp, and supply cannabis extracts to qualified Canadian and international business-to-business partners under their own brand.

  To meet growing requirements, we intend to produce our cannabis extractions for both recreational and medical use.

  In addition to providing at-cost analytical testing services to Adastra, Chemia provides full-suite cannabis analytical testing services to 3rd parties throughout the Province of British Columbia lower mainland.

  Our team can provide consulting and testing services for product formulation and development for cannabis product developers.

  During the year ended December 31, 2022, we had the following breakdown of revenues:

  -Our revenue is generated through bulkCannabis manufacturing revenues comprised of cannabis extractsproduct sales processed cannabis extract wholesalesof $15,613,320 and toll processing contracts within Canada. White label manufacturing and tolling revenues of $1,180,955.

  -Licensing revenues of $909,331

  -Cannabis consultation fees of $273,253

  -Referral revenues of $154,967

  27

  ---

  Revenues of $5,628,616 for the year ended December 31, 2021 consisted of bulk distillate sales of $2,188,924, packaged shatter sales of $1,709,990, vape cartridge sales of $1,050,235, licensing revenue of $385,119, toll processing revenue of $40,283 and other revenue of $254,065. Revenues of $2,499,355 for the year ended December 31, 2020 consisted of bulk distillate sales of $1,974,908, and toll processing revenue of $524,447.

  22

  ---

  Extraction

  To meet growing requirements, we intend to produce our cannabis extractions for both recreational and medical use:

  •● Indica and Sativa strains and combinations of both - for various medicinal purposes including anxiety, insomnia, pain, nausea and cancer treatment.

  •● Premium extracts are expected to have a higher market value but only when they provide a truly unique experience.

  Specific products developed by us will be initially limited by those currently permitted in the medicinal market and recreational market.

  Cannabis is a powerful stimulus that provides a unique experience to each user. With each variation comes a completely different experience. We understand the power that cannabis can have over people and the difference each strain can make. From pain-relief strains to euphoric "outer" body experiences, we anticipate having unique extracts for the desire of every consumer.

  We plan to process, sell and distribute high quality cannabis extracts currently permitted by Health Canada under the Cannabis Act. We plan to increase our product line offering for additional products to be manufactured per Health Canada regulations as permitted under the Cannabis Act.

  We plan to develop special product lines, each with its unique identifier and use to allow customers to use cannabis based on why they want to consume it. We expect that each product line will have a different strain, giving customers the ability to choose the kind of effect they need and want.

  Indica, Sativa and Hybrid strains are used to treat a wide variety of ailments. Each type of strain extract will be derived of a unique blend of premium cannabis plant material. We also intend to create a line of single-origin and handcrafted cannabis extract products.

  Our planned products, some of which are subject to legalization and/or obtaining necessary additional licenses (noted with "*"), are projected to include:

  • •      Bulk Low THC Cannabis Oil for tinctures;

  • •      Bulk CBD Oil without THC*;

    •     

  • Consumer packaged Low THC Cannabis Oil*;

    •     

  • Consumer packaged CBD Oil without THC*;

    •     

  • Bulk High THC Cannabis Oil (distillate);

    •     

  • Bulk Vaporizing pen formulations;

    •     

  • Bulk water-soluble (nano-emulsion) cannabis oils and distillate;

    •     

  • Bulk THC distillate Cannabis Gel Capsules (two-part);

    •     

  • Consumer packaged THC Cannabis Oil Tinctures;

    •     

  • Consumer packaged Vaporizing pens;

    •     

  • Consumer packaged THC distillate Cannabis Gel Capsules;

    •     

  • Bulk and consumer packaged hydrocarbon extracts;

    •     

  • Bulk and consumer packaged Cannabis infused cosmetics and topics*; and

    •     

  • Bulk and consumer dried flower*.

  2328

  ---

  We dependDuring the year ended December 31, 2022, we depended on the brand licensing agreement to CannMart Labs Inc. to bring our products to market in Canada. Per this agreement, CannMart Labs Inc. hashad an exclusive license to use the Company's brands in association with development, manufacture, production, promotion, marketing, packaging, distribution and sale of the following types of products:

  •     

  • Cannabis vaporizing pen cartridges and batteries;

    •     

  • Cannabis capsules;

    •     

  • Cannabis tincture bottles and tincture jars;

    •     

  • Cannabis syringes;

    •     

  • Cannabis terpene extracts (terp sauce); and

    •     

  • Cannabis concentrates in solid form such as shatter, wax, live resin, crystals (diamonds) produced with Butane Hash Oil (BHO) or Propane Hash Oil (PHO) processes.

  Per this brand licensing agreement, CannMart Labs Inc. fulfillsfulfilled sales orders of the Company'sour products across Canada and payspaid the Company 50% of gross profits earned from these sales on a quarterly basis. In return, CannMart Labs Inc. assistsassisted in the marketing of the Company'sour products to increase sales. This agreement is set to terminatewas terminated during 2023the year ended December 31, 2022 and since the acquisition of Phyto BrandCo, the Company has earned over $385,000 fromrecorded a loss on the agreement. We also intend to brand our products using proprietary trademarks to be acquired by or developed in house.termination of the licence agreement of $1,542,492.

  In addition, we anticipate we will provide other Health Canada cannabis license holders in the industry (Standard Cultivators or other Standard Processors) the ability to process cannabis into cannabis oils, distillate or other extract related formulations as a B2B service for a fee.

  NoApart from the loss on termination of the license agreement noted above, no part of our business is reasonably expected to be affected in the current financial year by either the renegotiation or termination of any contract.

  Cannabis and hemp biomass is widely available in the Canadian market, noting that there can be raw material price volality,volatility, with prices also varying depending on strain as well as quantity and quality of product available. Overall, due to certain oversupply of non-craft cannabis and hemp biomass in the Canadian markets, the price of cannabis and hemp biomass has generally reduced over the last couple years.

  Production Flow

  The production flow of the Facility was designed to maximize the use of the existing production area layout while meeting all the requirements for Cannabis regulations.

  2429

  ---

  Super Critical CO2 Production Flow Path

  

  The flow path above depicts the receiving process whereby dried cannabis flower and trim is brought into our extraction facility for supercritical CO2 extraction, cryogenic ethanol extraction and hydrocarbon extraction. The first step involves a receipt moisture test, weighing and input into the inventory control system.

  Following successful receipt, dried cannabis is then transferred into a temperature and humidity controlled secure vault until it is withdrawn for extraction. During the production process, dried cannabis is checked out of the secured vault (15) and enters production.

  When CO2 extraction is to be performed, cannabis is transported to one of two grinding stations where it is milled to a fine consistency (2) to maximize surface area and compactness to improve extraction efficiency.

  Following grinding the cannabis biomass is transferred to the Decarboxylation room (3) where it is heated in a vacuum and terpenes are extracted by a cold trap. These terpenes will be re-introduced to the extracted cannabis oil. The cannabis biomass is then extracted with supercritical CO2 (5) where crude cannabis oil is produced.

  The cannabis crude oil is then mixed with ethanol and stored for 24-48 hours during winterization (4) after which it is filtered using large stainless-steel filters under a vacuum to remove waxes and lipids (6,7,8).

  The remaining cannabis oil-ethanol mixture is processed through a rotary evaporator to remove and recycle all ethanol (8). The remaining cannabis oil then undergoes another distillation process in the Short Path Distillation equipment to further refine the oil to its purest form (10,11). If required, the cannabis distillate can be formulated to meet Cannabis Act regulations. Finally, the refined and properly dosed cannabis oil is filled into bottles (8) and packaged (9) for sale. The cannabis product can be sent to shipping (10A) or secure storage (10B).

  Spent biomass is removed from the CO2 extraction equipment (1) and transported to a caged storage area (2). Spent biomass is THC- and cannabinoid-free and will be disposed of through 3rd party composting (3).

  2530

  ---

  Cryogenic Ethanol Extraction Production Workflow

  

  When Cryogenic Ethanol extraction is to be performed, cannabis is transported to the Grinding room (2) to be filled into extraction bags. No milling is required.

  Once filled into bags, the cannabis moves into the Winterization Room (23) for ethanol extraction. Cannabis crude is generated and flows into the Filtration room (9) for secondary decarboxylation and devolatilization.

  The decarboxylated cannabis crude then undergoes another distillation process in the Short Path Wiped Film Distillation equipment to further refine the oil to its purest form (10,11). If required, the cannabis distillate oil can be formulated diluted to meet Cannabis Act regulations. Finally, the refined and properly dosed cannabis oil is filled into bottles (8) and packaged (9) for sale. The cannabis product can be sent to shipping (10A) or secure storage (10B).

  Spent biomass is removed from the Cryogenic Ethanol Extraction equipment (23) and transported to a caged storage area (2). Spent biomass is THC- and cannabinoid-free and will be disposed of through 3rd party composting (3).

  2631

  ---

  Hydrocarbon Extraction Production Flow

  

  When Hydrocarbon extraction is to be performed, cannabis is transported to the HAL booth (25) for extraction.

  Once filled into bags, the cannabis is extracted (25) and a cannabis extract is produced.

  The cannabis extract flows into Product Development (26) for hydrocarbon purge using vacuum ovens. Bulk purged extract can then be packaged (9) for sale. The cannabis product can be sent to shipping (10A) or secure storage (10B).

  Spent biomass is removed from the Hal Booth (25) and transported to a caged storage area (2). Spent biomass is THC- and cannabinoid-free and will be disposed of through 3rd party composting (3).

  Testing

  Chemia provides QA/QC and compliance testing services for licensed producers of cannabis and cannabis products under Health Canada regulations. Chemia also provides in-process testing services to help cultivators and processors optimize their processes. For QA/QC and compliance testing, any company holding a valid Health Canada cultivation or micro-cultivation, or processing license can send Chemia their sample. In addition to that, any dispensary representative, independent patient, and anyone else who wants to learn the chemistry and composition of their cannabis products can send samples for testing.

  Chemia expects to provide the following testing services:

  - Potency Testing

  o Fast, high sensitivity testing to determine the potency of cannabis products. Chemia's tests will determine the levels of THCA/THC and CBDA/CBD and their total equivalency. Potency can be determined on fresh/dried flower, oils, extracts and concentrates.

  - Microbial Contamination

  2732

  ---

  o Chemia will be outfitted to complete all Health Canada mandated microbial tests on fresh/dried flower, oils, extracts and concentrates. Including amounts of total yeast and mold, total aerobic microbial counts, bile-tolerant gram-negative bacteria, E. coli, and Salmonella. Upon request testing for S. aureus, and P. aeruginosa will be conducted.

  - Aflatoxins Analysis

  o Chemia's method is capable of fulfilling Health Canada requirements for the analysis of aflatoxins on dried cannabis flower, oils and extracts. Chemia will test for aflatoxins B1, B2, G1 and G2.

  - Heavy Metal Analysis

  o Cannabis is known to accumulate heavy metals in its tissues. As required by Health Canada, its lab can efficiently and accurately test dried flower, oil and extracts for lead (Pb), cadmium (Cd), mercury (Hg) and arsenic (As). Additional metal screening for trace elements can also be performed as needed.

  - Pesticide Screening

  o Regulations for pesticide use on cannabis are strict. Chemia will use a combination of high-tech analytical techniques for pesticides screening. This screening can be done for fresh/dried flower, oils, extracts and concentrates.

  - Residual Solvent Analysis

  o To ensure the safety of customer's products and maintain compliance with Health Canada regulations, Chemia has developed tests to determine the quantity of residual solvents in cannabis oils, extracts and concentrates. Chemia can determine the quantity of methanol, ethanol, acetone, isopropanol (isopropyl alcohol), acetonitrile, hexane, heptane and pentane.

  - Loss On Drying

  o Before sale in Canada the moisture content of all dried cannabis flower must be reported. Chemia's tests will provide a customer with the percent moisture of customer's products.

  - Foreign Matter

  o As per Health Canada regulations Chemia will visually inspect customer's cannabis products for the presence of foreign material.

  -

  - Cannabinoid Profiling

  o In addition to potency testing, Chemia can quantify 14 unique cannabinoids in cannabis products. The list of cannabinoids includes Tetrahydrocannabinolic acid (THCA), Δ9-Tetrahydrocannabinol (Δ9-THC), Cannabidiolic acid (CBDA), Cannabidiol (CBD), Cannabinol (CBN), Cannabigerolic acid (CBGA), Cannabigerol (CBG), (±)-Cannabichromenic acid (CBCA), (±)-Cannabichromene (CBC), Tetrahydrocannabivarinic acid (THCVA), Tetrahydrocannabivarin (THCV), Cannabidivarinic acid (CBDVA), Cannabidivarin (CBDV) and Cannabigerovarinic acid (CBGVA).

  - Terpene Analysis

  o Flavour and aroma of cannabis come from its terpene profile. That's why Chemia can quantify 39 terpenes commonly detected in cannabis. Chemia's tests can determine the quantities of the monoterpenes, alpha-Pinene, Camphene, Sabinene, beta-Pinene, beta-Myrcene, alpha-Phellandrene, (1S)-(+)-3-Carene, alpha-Terpinene, (R)-(+)-Limonene, Eucalyptol, Ocimene, gamma-Terpinene, Sabinene Hydrate, L-(-)-Fenchone, Terpinolene, Linalool, (1R)-Endo-(+)-Fenchyl Alcohol, (1S)-(-)-Camphor, (-)-Isopulegol, Isoborneol, (+/-)-Borneol, Hexahydrothymolalpha-Terpineol,gamma-Terpineol, Geranyl Acetate, (+)-Pulegone, Geraniol, Nerol. CAI can also test for sesquiterpenes including, alpha-Cedrene, trans-Caryophyllene, (-)-Caryophyllene Oxide, alpha-Humulene, Valencene, cis-Nerolidol, trans-Nerolidol, Guaiol, (+)-Cedrol and (-)-Alpha-Bisabolol.

  2833

  ---

  Although Chemia will be required to perform all cannabis testing specified in the Cannabis Act regulations, it is permitted to stage purchase of expensive analytical equipment and certify the various tests in a staggered manner as a way of reducing capital expenditures. Further, Chemia plans to finance used equipment that has been certified from the manufacturer to reduce the overall cost and allow for the 3rd party testing revenue to reduce the cost of equipment financing.

  Principal Markets

  There are two broad segments, medical use and recreational. There is growth and greater acceptance in the medical use of CBD products for pain management, appetite control and cell generation involved in the treatment of cancer, MS, epilepsy and AIDS.

  Clients are to include direct retail as well as wholesaling to distributors. The regulations also allow the export of products, subject to obtaining the necessary permitting. To maintain a stable supply in the market that meets the demand level, we expect to utilize a variety of distribution channels. Our online presence will also help to connect with the B2B customers. We will also be targeting other businesses that are licensed by Health Canada for product testing, white labelling products and toll processing.

  The retail market for cannabis products is still developing and there is a need for more participants within the industry. Health practitioners and doctors play a key role by introducing their patients to cannabis as an alternative treatment. We anticipate designing marketing campaigns to create relationships with health care professionals including education, forums, training, printed literature, and media. Healthcare professionals employed at our clinics will provide consultations to patients and may market our products to them depending on the patients' needs. The Company aims to create relationships with healthcare professionals to support the marketing of our products, mainly through the use of social media. In April 2021, the Company also entered into a marketing services agreement with Hybrid Financial Ltd. to assist in all aspects of a marketing campaign for the Company.

  Within the recreational use segment, we view the following areas where there are potential growth opportunities:

  • 25-to-35-YEAR-OLD URBAN PROFESSIONALS: The 25-to-35 "yuppie" market prefer the upscale branding approach.

  • ATHLETES: This target group is a blend of medical and recreational use, seeking CBD products for cell generation and healing properties.

  • BABY BOOMERS: This was the original "hippie" generation who likely experimented in their youth. Now, largely with grown children, not needing to set moral standards, or frankly seeing the benefits of legalizing an industry to protect users from indiscriminate processors, they have become more accepting of legalization.

  Competitive Conditions

  We compete with other licensed cannabis processors and cannabis testers in Canada. We anticipate that competition from new participants into the market will increase in the short-to-mid-term, as existing applications in queue with Health Canada are processed and approved. However, we also believe that many current and prospective applicants will not be able to obtain the necessary funding to conduct the necessary construction activities necessary to submit an initial application or in the case of current applicants, final application. Consolidation in this industry has already started, and management of our company believes that it will likely continue and increase as more producers and vendors are licensed by Health Canada under the Cannabis Act.

  Seasonality

  Our business is not subject to seasonality fluctuations.

  Employees

  We have 2963 employees as of the date of this annual report.

  2934

  ---

  Organizational Structure

  We have one direct wholly owned subsidiary, Adastra, a British Columbia corporation. Adastra has six wholly owned direct and indirect subsidiaries incorporated in British Columbia, Canada: (1) Adastra Labs Inc., for the extraction and concentrates production facility; (2) Chemia Analytics Inc., for a cannabis testing and analysis laboratory; (3) 1178562 B.C. Ltd., the owner of the Facility; (4) Adastra Brands Inc., a holding company for future branding of cannabis products which has no activities to date; (5) PerceiveMD, a direct subsidiary of Adastra Labs Inc. and the owner of a multidisciplinary medical clinic focusing on treatments with cannabis and psychedelics;certain controlled substances; and (6) 1204581, a direct subsidiary of Adastra Labs Inc. and the owner of intellectual property rights for the Phyto Extractions brand.

  Although Adastra and Chemia are co-located at the Facility in Langley, British Columbia, Canada, they are separate legal entities to allow Chemia to provide objective production testing for Adastra at cost and keep these analytical testing activities separate from Adastra production. We through Adastra and Chemia have acquired two licenses from Health Canada to become a legal processor of cannabis in Canada through Adastra and to be a licensed cannabis analytical testing laboratory with Chemia.

  C. Property and Equipment

  Through our wholly owned subsidiary, 1178562 B.C. Ltd., we own the Facility. See "Item 4.B Business Overview - Facility."

  Item 4A. Unresolved Staff Comments

  Not applicable.

  Item 5. Operating and Financial Review and Prospects

  The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited financial statements for the years ended December 31, 20212022 and 20202021 and related notes, included in this Form 20-F annual report. Our audited consolidated financial statements included in this annual report were prepared in accordance with International Financial Reporting Standards ("IFRS"), as adopted by the International Accounting Standards Board.

  The preparation of the consolidated financial statements in conformity with these accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. On an on-going basis we review our estimates and assumptions. The estimates were based on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results are likely to differ from those estimates or other forward-looking statements under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations. Our actual results may differ materially as a result of many factors, including those set forth under the headings entitled "Cautionary Note regarding Forward Looking Statements" and "Risk Factors" herein.

  All monetary amounts are expressed in Canadian dollars, except number of shares or as otherwise indicated.

  A. Operating Results

  Overall Performance

  TotalThe Company had revenue of $18,131,826 for the year ended December 31, 2022 compared to $5,628,616 for YTD 2021 compared to $2,499,355 for YTD 2020.the year ended December 31, 2021. Excise taxes of $4,836,748 were incurred during the year ended December 31, 2022. This represents a 222% increase in revenues from the prior year.

  Net lossThe Company achieved a gross profit of $2,749,939$6,112,049 for YTD 2021the year ended December 31, 2022 compared to $7,615,864$1,943,691 in the prior year, achieving a growth of 214%. This was achieved by increasing the economies of scale of production as well as managing the costs of inputs of production. Inflation had a minimal impact on the costs of inputs for YTD 2020.the Company as these were offset by the Company being able to purchase larger quantities as lower rates. In addition, the Company has continued its transition to increase the sales of higher margin products.

  Cash used in operating activities was $1,054,093 for YTD 202135

  ---

  The Company had cash of $1,013,867 at December 31, 2022 compared to $2,807,720 for YTD 2020.

  Cash$744,541 as at December 31, 2021 of $744,541 compared2021. The Company continues to $1,145,461 as at December 31, 2020closely monitor and manage cash.

  Working capital deficit as at December 31, 2021 of $1,120,6132022 was $3,665,081 compared to working capital surplus of $105,093$1,120,613 as at December 31, 2020.2021. This includes the $3,500,000 mortgage in both years, which is expected to be renewed for a longer term and on more favourable conditions.

  30

  ---

  Mortgage payable as atOperating expenses increased from $4,335,429 in the prior year to $6,912,045 during the year ended December 31, 2021 $3,501,5542022. This represents and increase in operating expenses of 59% compared to $2,442,830 as atrevenue growth of 222% and gross profit growth of 214%.

  The loss from operations decreased from $2,391,738 in the prior year to $799,996 during the year ended December 31, 2020.2022. This represents a 67% decrease in loss from operations from the prior year.

  For the year ended December 31, 2022, the Company had a net loss of $4,281,639 (2021 - $2,749,939) which included a one-time charge to goodwill for the impairment of PerceiveMD as the Company has not realized the expected synergies in business operations in the originally planned timeframe. The Company also had a one-time loss on the termination of the license agreement related to the Phyto BrandCo, which allows the Company to bring the brand fully in-house for production.

  The Company has a single reportable segment: the provision of goods and services to the cannabis industry in Canada. All the Company's revenues are generated in Canada, and its non-current assets are located in Canada.

  Operations and Facility

  The Company's focus for the year ended December 31, 2021,2022 included the expansion and increased efficiency of its operations at its centralized processing facility in Langley, BC. On March 13, 2021, the Company received an amendment to its Processing License authorizing the sale of cannabis extract, cannabis edibles, and cannabis topicals. On April 16, 2021, the Company received an amendment to its Analytical Testing License allowing for organoleptic testing of its products. In April 2021, the Company commissioned its hydrocarbon extraction line and in August 2021, it submitted a further sales licence amendment for dried flower and a controlled substance dealer's licence for cannabis products.

  As of the date of this annual report, the Company is focused on generating revenue from four primary verticals: wholesale activities;processing cannabis for sale to the recreational and medical markets; service fees for cannabis consultations; educational fees for clientsclients' referral to licensedlicenced cannabis producers; and the licensing of cannabis trademarks.

  As of April 23, 2020 the Company has completed the commissioning and commencement of operations at its 13,00013,035 square feet facilityfoot Facility in Langley, British Columbia (the "Langley Facility").Columbia. It currently operates a primary supercritical CO2 extraction line for the production of crude cannabis/hemp extracts, wiped film short path distillation plant for the production of high potency cannabis distillate, a formulation, filling line and packaging line for the manufacture of tincture bottles and vaporizer products and shatter as consumer-packaged goods.

  During September 2020, the Company installed and commissioned its cryo-ethanol extraction production line that triples the Company's cannabis oil production capacity while reducing overall costs. This production line allows the re-purposing of the CO2 supercritical extraction line for other cannabis concentrate products such as high terpene full spectrum extracts.

  During April 2021, the Company completed the installation of its hydrocarbon extraction line, allowing it to produce Shatter products for the Canadian Market. This high performance hydrocarbon extractor will allow the Company to process over 400 kg per day of dried cannabis into a variety of shatter cannabis products.

  Wholesale Bulk Extracts Production

  During the year ended December 31, 2021,2022, the Company continued processing its own inventory of dried cannabis through supercritical CO2, cryo-ethanol and hydrocarbon extraction lines and distillation lines for the purpose of selling the resulting bulk cannabis concentrates to licensed clients or using it to fulfill contract manufacturing orders, primarily for vape cartridges. The Company has procured all of its bulk shipments of dried cannabis for its wholesale production lines from various licensed cultivators under the Cannabis Act Duringduring the year ended December 31, 2021, the Company recognized revenue of $5,628,616.2022.

  3136

  ---

  SELECTED FINANCIAL INFORMATION

  Results of Operations

  Consolidated results of operations for the year ended December 31, 20212022 compared to the year ended December 31, 2020.2021.

  		FYE 2021 (IFRS)			FYE 2020 (IFRS)			FYE 2022 (IFRS)			FYE 2021 (IFRS)
  		$			$			$			$
  Gross Revenue		5,628,616			2,499,355			18,131,826			5,628,616
  Excise Taxes								(4,836,748	)		-
  Cost of Sales		(3,684,925	)		(1,713,774	)		(7,183,029	)		(3,684,925	)
  Gross Profit		1,943,691			785,581			6,112,049			1,943,691
  Operating expenses		(4,335,429	)		(7,950,595	)		(6,912,045	)		(4,335,429	)
  Net (loss) income and comprehensive (loss) income		(2,749,939	)		(7,615,864	)		(4,281,639	)		(2,749,939	)
  Total assets		28,755,450			13,736,950			31,803,945			28,755,450
  Current liabilities		5,341,267			3,590,794			12,660,207			5,341,267

  Revenues increased to $18,131,826 during the year ended December 31, 2022, compared to $5,628,616 during the year ended December 31, 2021, compareddue to $2,499,355 duringnew revenue from a range of provincial distributors which were not present in 2021. These sales augmented the year ended December 31, 2020,existing revenue from increasedthe processing of cannabis biomass for third partythird-party licensed producers, and in-house distillate production, hydrocarbon extraction, and licensing revenues from the acquisition of Phyto BrandCo.BrandCo, and MSP remittance and referral revenue from the acquisition of PerceiveMD.

  Excise taxes of $4,836,748 were incurred during the year ended December 31, 2022. There were no excise taxes in the prior year due to the Company not selling to any distributors or retailers during the year ended December 31, 2021.

  Cost of sales increased to $7,183,029 during the year ended December 31, 2022, compared to $3,684,925 during the year ended December 31, 2021, compared to $1,713,774 during the year ended December 31, 2020, andas a result of increased sales. Cost of sales consists of biomass, packaging, production labour, solvents and an allocation of production overheads such as facility costs and amortization of production equipment.

  For the year ended December 31, 2021,2022, the Company had operating expenses of $6,912,045 and loss and comprehensive loss of $4,281,639, compared to operating expenses of $4,335,429 and loss and comprehensive loss of $2,749,939 compared to operating expenses of $7,950,595 and loss and comprehensive loss of $7,615,864 during the year ended December 31, 2020.2021.

  The decreaseincrease in operating expenses and net loss and comprehensive loss were the result of the Company's expenses with respect to advertising and promotion, professional fees and consulting, and share-based payments having decreased as the Company moved from its startup phase into production and expansion of its business during the year ended December 31, 2021, offset by a rise in wages and salary costs.year. The most significant changes in operating expenses and other expenses were as follows:

  	•	Advertising and promotion decreased to $455,090 during the year ended December 31, 2021, compared to $749,258 during the year ended December 31, 2020, due to the Company developing a more focused investor awareness campaign and being more established in the market.
  	•	Professional fees and consulting decreased to $585,908 during the year ended December 31, 2021, compared to $704,297 during the year ended December 31, 2020, primarily due to the decrease of consultants needed to prepare the extraction process, commissioning of equipment and testing.
  	•	Share-based payments decreased to $890,523 during the year ended December 31, 2021, compared to $5,332,500 during the year ended December 31, 2020, as a result of 1,148,333 stock options granted during YTD 2021 (YTD 2020 - 4,206,667); all granted options vest immediately.
  	•	Wages and salaries increased to $1,128,610 during the year ended December 31, 2021, compared to $526,327 during the year ended December 31, 2020, due to increased hiring activity and production output related to the Langley Facility.
  	•	During the year ended December 31, 2021, the Company incurred impairment of property and equipment of $150,000 related to an ERP software in software in development that the Company determined would not be completed. No impairment of property and equipment was recorded during the year ended December 31, 2020.
  	•	During the year ended December 31, 2021, the Company recognized a provision for expected credit losses of $134,083 (Q4 2020 - $nil) related to a significantly aged account receivable which management deemed to have uncertain collectability.

  • Advertising and promotion increased to $1,277,728 during 2022, compared to $455,090 during 2021, as the Company raised awareness of its operational successes and incurred significant travel by the sales team as it expanded its reach to more provincial distributors and launched both the Endgame and Phyto brands through both digital and face to face marketing.
  • Data program expenses of $1,042,216 during 2022 compared to $288,804 during 2021. These costs are related to a Cannabylitics data sharing program subscribed to by Phyto BrandCo.
  • Depreciation and amortization charged to operating expenses increased to $501,364 during 2022, compared to $272,616 during 2021 due to the additions of trademarks and patient relationships from the acquisitions of Phyto BrandCo and PerceiveMD during the year ended December 31, 2021.
  • Office expenses increased to $685,266 during 2022, compared to $323,778 during 2021 due to additional costs in relation to computer, internet, utilities, meals and entertainment as well as equipment and vehicle rentals.
  • Professional fees and consulting expenses increased to $910,564 in 2022, compared to $585,908 during 2021 due to increased legal, audit and accounting fees associated with the growing operations and regulatory compliance.
  • Repairs and maintenance expenses were $219,169 in 2022 compared to $nil in 2021. These costs are related to refrigeration suppliers, mechanical services and other maintenance services.

  3237

  ---

  • Share-based payments decreased to $138,713 during 2022, compared to $890,523 during 2021, as the Company granted 300,000 stock options to a certain director on August 22, 2022. In the prior year, the Company granted 1,148,333 stock options to certain employees, consultants, directors and officers.
  • Wages and salaries increased to $1,834,082 during 2022, compared to $1,128,610 during 2021, due to increased hiring activity and production output and the additional staff taken on following the Phyto BrandCo acquisition.

  B. Liquidity and Capital Resources

  The Company's objectives when managing its liquidity and capital structure are to support further advancement of the Company's business objectives and existing service offerings, as well as to ensure that the Company is able to meet its financial obligations as they come due.

  Cash and working capital

  As at December 31, 20212022, the Company hashad a working capital deficit of $1,120,613 (December 31, 2020$3,665,081 (2021 - working capital surplus of $105,093)$1,120,613).

  As at December 31, 2021,2022, the Company had a current mortgage payable liability of $3,501,554 this$3,507,389 (2021 - $3,501,554). The fifth mortgage matureshas a maturity date of November 1, 2023 and is secured by the mortgage property and building improvements. The mortgage bears interest at the greater of 9.75% or the prime rate plus 4.30% per annum, calculated monthly. The Company expects to renew the mortgage on July 1, 2022.more favourable terms. If the Company is able to secure a long-term mortgage, the working capital of the Company will significantly improve. Also, the Company is considering applying for a line of credit to assist with the Company's growth and ensure the Company has enough liquidity in the purchasing of inputs of production.

  As at December 31, 2022, the Company has no working capital requirements.

  Cash flow activity

  Consolidated cashflows for the year ended December 31, 20212022 compared to the year ended December 31, 2020.2021.

  		FYE 2021 (IFRS)			FYE 2020 (IFRS)			FYE 2022 (IFRS)			FYE 2021 (IFRS)
  		$			$			$			$
  Cash used in operating activities		(1,054,093	)		(2,807,720	)		1,319,111			(1,054,093	)
  Cash provided by (used in) financing activities		915,984			3,395,096			(22,548	)		915,984
  Cash provided used in investing activities		(262,811	)		(1,818,741	)		(1,027,237	)		(262,811	)
  Net increase (decrease) in cash		(400,920	)		(1,231,365	)		269,326			(400,920	)
  Cash, beginning of the year		1,145,461			2,376,826			744,541			1,145,461
  Cash, end of the year		744,541			1,145,461			1,013,867			744,541

  Cash provided by operating activities of $1,319,111 during the year ended December 31, 2022 (2021 - used $1,054,093) was the result of operating losses as noted in Results of Operations which were more than offset by working capital movements such as the increase in accounts payable and accrued liabilities as the Company expands. During 2021, the cash used in operating activities was the result of cash spent on inventory as well as prepaid expenses and deposits, offset by cash generated from revenue activity.

  Cash used in operatingfinancing activities of $1,054,093 (YTD 2020$22,548 during the year ended December 31, 2022 (2021 - $2,807,720)provided $915,984) was the result significant addition to amounts receivableof interest paid on the mortgage payable and cash spentpayments on inventory.the lease liability. This was offset by $300,000 received as proceeds from a short-term loan. During 2021, the prior year there was a significant cash outflows from cash spend on operating expenses such as advertising and promotion and professional fees in addition to cash spent on inventory.

  Cash provided by financing activities of $915,984 (YTD 2020 - $3,395,096) was the result of cash received from mortgage refinancing and units issued for cash offset by interest payments of the mortgage payable.  During the prior period cash was provided by the issuance of unit financing, warrants exercised and proceeds from the government loan offset by interest payments ofon the mortgage payable.

  Cash used in investing activities of $262,811 (YTD 2020$1,027,237 during the year ended December 31, 2022 (2021 - $1,818,741)$262,811) was the result of cash payments made for the purchase of property and equipment offsetand long-term excise stamp deposits while the cash provided by investing activities in 2021 was the result of net cash received from the acquisitions of Perceive MDPerceiveMD and Phyto BrandCo. In the prior period cash used in investing activities was due toBrandCo offset by cash payments made for the purchase of property and equipment.

  38

  ---

  Capital resource management

  The Company defines capital as the components of shareholders' equity. The Company's objectives when managing capital are to support further advancement of the Company's business objectives, as well as to ensure that the Company is able to meet its financial obligations as they come due.

  The Company manages its capital structure to maximize its financial flexibility making adjustments to it in response to changes in economic conditions and the risk characteristics of the underlying assets and business opportunities. The Company relies on the expertise of the Company's management to sustain the future development of the business. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable.Therereasonable. There were no changes in the Company's approach to capital management during the years ended December 31, 2021.2022. The Company is not subject to externally imposed capital requirements.

  33

  ---

  Tabular Disclosure of Contractual Obligations

  As of December 31, 2021,2022, we had the following contractual obligations and commitments:

  					Payments due by period															Payments due by period
  Contractual obligations		Total			Less than 1 year			1-3 years			3-5 years			More than 5 years			Total			Less than 1 year			1-3 years			3-5 years			More than 5 years
  		$			$			$			$			$			$			$			$			$			$
  Accounts payable and accrued liabilities		1,829,025			1,829,025			-			-			-			8,545,048			8,545,048			-			-			-
  Loan payable																	314,555			314,555			-			-			-
  Lease liability																	78,309			23,205			55,104			-			-
  Mortgage payable		3,500,000			3,500,000			-			-			-			3,822,505			3,822,505			-			-			-
  Lease liability		36,912			13,423			23,489			-			-
  Government loan		60,000			-			60,000			-			-			60,000			-			60,000			-			-
  Total		5,425,937			5,342,448			83,489			-			-			12,820,417			12,705,313			115,104			-			-

  Off-Balance Sheet Arrangements

  We have not engaged in any off-balance sheet arrangements such as obligations under guarantee contracts, a retained or contingent interest in assets transferred to an unconsolidated entity, any obligation under derivative instrument or any obligation under a material variable interest in an unconsolidated entity that provides financing, liquidity, market risk or credit risk support to our company or engages in leasing or hedging services with our company.

  C. Research and Development

  We do not currently have any patents or intellectual property arising from research and development, although we do own intellectual property rights including the Phyto Extractions brand.

  D. Trend Information

  We do not know of any trends, commitments, events, or uncertainty that are expected to have a material effect on our company's business, financial condition, or results of operations other than as described in the section "Risk Factors" and in the section entitled "Quantitative and Qualitative Disclosures About Market Risk".

  E. Critical accounting estimates

  The preparation of the Company's consolidated financial statements in conformity with IFRS requires management to make judgements, and estimates based on assumptions about future events that affect the application of accounting policies and the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

  Theexpenses. Management continually evaluates these judgements, estimates and associated assumptions are based on historical experience and various other factors, including expectations of future events that are believed to be reasonable under the circumstances,circumstances. Actual results may differ from these estimates and judgements which may cause a material adjustment to the results of which form the basis of making the judgements about carrying valuesamounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.liabilities.

  39

  ---

  The areas which require management to make critical judgments include:

  Going concern

  The consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The assessment of the Company's ability to source future operations and continue as a going concern involves judgment. Estimates and assumptions are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. If the going concern assumption werewas not appropriate for the consolidated financial statements, then adjustments to the carrying value of assets and liabilities, the reported expenses and the consolidated statement of financial position would be necessary. Such adjustments would be material.

  34

  ---

  Impairment of property and equipment

  Property and equipment are reviewed for indicators of impairment at each reporting period end or whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds its recoverable amount. The recoverable amount of an asset is the higher of its fair value, less costs to sell, and its value in use. If the carrying amount of an asset exceeds its recoverable amount, an impairment charge is recognized immediately in profit or loss by the amount by which the carrying amount of the asset exceeds the recoverable amount. If an impairment loss subsequently reverses, the carrying amount of the asset is increased to the lesser of the revised estimate of recoverable amount, and the carrying amount that would have been recorded had no impairment loss been recognized previously.

  Assessment of the transactions as asset acquisitions or business combinations

  Determination of whether a set of assets acquired and liabilities assumed constitute the acquisition of a business or asset requires the Company to make certain judgments as to whether or not the assets acquired and liabilities assumed include the inputs, processes and outputs necessary to constitute a business as defined in IFRS 3 - Business Combinations. If an acquired set of assets and liabilities includes goodwill, the set is presumed to be a business. The values assigned to common shares and the allocation of the purchase price to the net assets in the acquisition are based on numerous estimates and judgements of the relative fair values of net assets.

  Business combinations

  Judgement was used in determining whether the acquisitions of PerceiveMD and Phyto BrandCo were a business combination or an asset acquisition. Estimates were made as to the fair value of assets and liabilities acquired. In certain circumstances, such as the valuation of equipment, intangible assets and goodwill acquired, the Company may rely on independent third-party valuators. The Company measured all the assets acquired and liabilities assumed at their acquisition-date fair values. The excess of the consideration paid over the acquisition-date fair values of the net assets acquired, was recognized as goodwill as of the acquisition date in business combination.

  In a business combination, all identifiable assets and liabilities acquired are recorded at their fair values, including the total consideration paid by the Company. One of the most significant estimates relates to the determination of the fair value of these assets and liabilities including assessing the fair value of any identifiable intangible assets. For any intangible asset identified, due to the complexity of determining its fair value, an independent valuation expert may be engaged to measure the fair value, using appropriate valuation techniques, which are generally based on a forecast of the total expected future net cash flows. The evaluations are linked closely to the assumptions made by management regarding the future performance of the assets concerned and any changes in the discount rate applied. For any form of consideration paid by the Company, depending on the type of consideration paid and the complexity of determining its fair value, an independent valuation expert may be engaged to measure the fair value. In the event that there is contingent consideration in an acquisition management makes assumptions as to the probability of the consideration being paid.

  40

  ---

  The information about significant areas of estimation uncertainty considered by management in preparing thesethe financial statements is as follows:

  COVID-19 estimation uncertainty

  The coronavirus pandemic continues to have global impacts on workforces, economies, and financial markets. It is not possible for the Company to predict the duration or magnitude of any adverse effects that the pandemic may have on the Company's business or ability to raise funds. As of the date of these financial statements,this annual report, COVID-19 has had minimal impact on the Company's ability to conduct its operations but may impact the Company's ability to raise funding should restrictions related to COVID-19 be expanded in scope.

  Inventory

  The Company reviews the net realizable value of, and demand for, its inventory regularly to provide assurance that recorded inventory is stated at the lower of cost or net realizable value. Factors that could impact estimated demand and selling prices include competitor actions, supplier prices, government regulations, and economic trends.

  The weighted average costing method uses estimates in the allocation of direct and indirect inputs in the production of multiple product categories. These estimated allocations could be impacted by variations in manufacturing yields in production.

  Useful lives and depreciation of property and equipment and intangible assets

  The depreciation methods and useful lives reflect the pattern in which management expects the assets' future economic benefits to be consumed by the Company. Judgments are required in determining these expected useful lives.

  35

  ---

  Goodwill and intangible asset impairment

  Goodwill acquiredManagement uses estimates in a business combination is reviewed for impairment at each reporting period end or whenever events or changes in circumstances indicate that the carrying amount of the underlying goodwill exceeds its recoverable amount of the associated CGU. The recoverable amount of a CGU is the estimate of future cashflows generated by the CGU, based on management's assumptions. If the carrying amount of goodwill exceedsdetermining the recoverable amount of intangible assets and goodwill. The determination of the CGU, anrecoverable amount for the purpose of impairment chargetesting requires the use of significant estimates, such as:

  • future cash flows;
  • terminal growth rates; and
  • discount rates.

  Management regularly evaluates these estimates and assumptions. Revisions to accounting estimates are recognized in the period in which the estimate is recognized immediatelyrevised if the revision affects only that period or in profit or loss bythe period of the revision and future periods if the revision affects both current and future periods.

  Judgment is also applied in choosing methods of amortizing intangible assets that management believes most accurately represent the consumption of those assets and are most representative of the economic substance of the intended use of the underlying assets. A change in the estimate would result in a change in the amount byof amortization and, as a result, a charge to net loss recorded in the period in which the change occurs, with a similar change in the carrying amountvalue of the goodwill exceedsasset in the recoverable amount.statement of financial position.

  Valuation of receivables

  The Company recognizes an impairment loss allowance for expected credit losses on trade accounts receivable using a probability-weighted estimate of credit losses. In its assessment, management estimates the expected credit losses based on actual credit loss experience and informed credit assessment, taking into consideration forward-looking information. If actual credit losses differ from estimates, future earnings would be affected.

  41

  ---

  Valuation of share-based compensationpayments

  The Company uses the Black-Scholes option pricing model for valuation of share-based compensation.payments. Option pricing models require the input of subjective assumptions including expected price volatility, risk-free interest rate, and forfeiture rate. Changes in the input assumptions can materially affect the fair value estimate and the Company's earningsexpenses and equity reserves.

  Income taxes

  In assessing the probability of realizing income tax assets, management makes estimates related to expectation of future taxable income, applicable tax opportunities, expected timing of reversals of existing temporary differences and the likelihood that tax positions taken will be sustained upon examination by applicable tax authorities. In making its assessments, management gives additional weight to positive and negative evidence that can be objectively verified.

  Additional 2022 and Year-To-Date Highlights

  On February 9, 2023, the Company announced that it had terminated a legacy supply agreement for the Company's Phyto Extractions Brand. The household brand for legacy cannabis concentrates was 100% acquired as part pf the acquisition of Phyto Brandco. A legacy licence agreement remained in place following the acquisition, whereby Phyto utilized a third party's licensing status with Health Canada to exclusively package and sell its popular Phyto branded cannabis consumer packaged products on its behalf, in consideration for payment of royalties back to Phyto (the "Phyto Licence Agreement"). On August 30, 2022, Adastra announced it had entered into an agreement with the third party, whereby Adastra had the right and option to terminate the Phyto Licence Agreement subject to certain conditions which have now been met.

  On February 14, 2023, the Company announced that it had appointed Lachlan McLeod as the Chief Financial Officer.

  On March 15, 2023, the Company announced that it has been served with a civil claim filed in the Supreme Court of British Columbia pursuant to the Class Proceedings Act, R.S.B.C. 1996, c. 50 alleging that the Company's press release of February 22, 2023 (the "Press Release") misstated certain material facts which misled the plaintiff in the claim. The suit also names the Company's subsidiary ALI and the Company's Chief Executive Officer, Mr. Michael Forbes. The Company denies the allegations in the claim and specifically that the Press Release was misleading, and the Company intends to vigorously defend against these allegations should the class action be certified. Currently, no specific amount of damages is claimed.

  On March 16, 2023, the Company announced that it has engaged Hybrid Brand Management ("Hybrid") to expand its sales coverage and product sell-through in British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario, with regular in-store activations and staff product education sessions. Hybrid serves approximately 2,800 cannabis retailers in Canada. In addition, the Company announced that during January and February 2023 it has shipped a record volume of 379,343 grams of cannabis products and achieved this result with over 1,300 orders.

  The Company announced it has entered into an investor relations agreement with Apollo Shareholder Relations Ltd. ("Apollo") dated April 3, 2023 to provide investor relations services. The investor relations agreement provides for a monthly fee of $15,000 CAD for an initial three-month term, continuing on a monthly basis thereafter. Either party may terminate the agreement by providing 30 days' written notice. The investor relations services were to commence on or about April 10, 2023.

  42

  ---

  Item 6. Directors, Senior Management and Employees

  A. Directors and Senior Management

  The following table sets forth the name, office held, age, and functions and areas of experience in our company of each of our directors and senior management:

  Name, Office Held, Age	Area of Experience and Functions in Our Company
  Michael Forbes Chief Executive Officer and Director Age: 42 Age: 41	As our Chief Executive Officer and Chairman of the board of directors, Mr. Forbes is responsible for strategic planning and operations, as well as managing our relations with our lawyers, regulatory authorities and investor community; as a director, Mr. Forbes supervises our management and helps to ensure compliance with our corporate governance policies and standards. Mr. Forbes is a member of our audit committee.
  Oliver Foeste Lachlan McLeod Chief Financial Officer Age: 36 Age: 45	As our Chief Financial Officer, Mr. FoesteMcLeod is responsible for the management and supervision of all of the financial aspects of our business. Mr. FoesteMcLeod assists in strategic planning, oversees capital planning and capital raising, budgeting, financial reporting and risk management. In performing his duties, Mr. FoesteMcLeod maintains relationships with our auditors, legal counsel, banks, and other financial stakeholders.
  George Routhier Director Age: 68	As an independent director, Mr. Routhier supervises our management and helps to ensure compliance with our corporate governance policies and standards. Mr. Routhier is a member of our audit committee.
  Paul Morgan Director Age: 41 Age: 40	As an independent director, Mr. Morgan supervises our management and helps to ensure compliance with our corporate governance policies and standards. Mr. Morgan is a member of our audit committee.
  Smoke Wallin Director Age: 56	As an independent director, Mr. Wallin supervises our management and advises on business strategy, financing and cannabis regulation compliance. Mr. Wallin is a member of our audit committee.

  36

  ---

  The following is a brief account of the business experience of each of our directors and senior management.

  Michael Forbes, Chief Executive Officer and Director

  Michael Forbes became a director effective April 29, 2021 and our Chief Executive Officer effective May 3, 2021. Mr. Forbes is a registered pharmacist. Mr. Forbes has founded five cannabis medical clinics under the Concord Medical Clinic umbrella, built Clarity Cannabis and Honeycomb Cannabis to over 10 locations, and also founded the cannabis licensed production facility, Sitka Weed Works, in Canada. Having medical experience of over 16 years, Mr. Forbes has also built and operated pharmacy chains across British Columbia and Alberta, and founded a dozen medical clinics, including 3 methadone clinics in order to protect the public from drug diversion and increase accessibility to medicine. Mr. Forbes graduated from the University of British Columbia in 2002 with a BSc. in Pharmaceutical Sciences, also achieving additional certification in Hormone Restoration, Age Management Medicine, and more recently, Cannabis Plant Production and Facility Management from Kwantlen Polytechnic University. He was elected to attend the Ivey School of Business for Canada's Top 40 under 40 in 2017 where he received an honorary MBA.

  Oliver Foeste,Lachlan McLeod, Chief Financial Officer

  Oliver Foeste,Lachlan McLeod, CPA CA became our Chief Financial Officer effective July 13, 2021.January 1, 2023.

  Mr. Foeste is the founder and Managing Partner of Invictus Accounting Group LLPLachlan McLeod has experience in public practice, having worked as an auditor for a Big 4 accounting firm for four years, and has significant executive, director, finance,served as a fractional CFO for multiple public companies. Lachlan has a record of helping businesses meet financial and restructuring experience acrossregulatory reporting requirements. Lachlan is a number of industry sectors.  Prior to founding Invictus Accounting Group LLP, Mr. Foeste wasChartered Professional Accountant (CPA) with a Bachelor's degree in senior finance and accounting roles at Toronto Stock Exchange, TSX Venture Exchange, and New York Stock Exchange listed issuers, and earned his CPA at DeloitteScience with an Economics major and a boutique tax advisory firm.

  George Routhier, Director

  George Routhier becameBusiness minor from the University of Victoria, and a directorDiploma of our company effective December 19, 2019. Mr. Routhier isAccounting from the CEOSauder School of Pipedreemz Inc., a cannabis licensing regulations consulting company responsible forBusiness at the successful licensingUniversity of approximately 30 percent of cannabis Licensed Producers across Canada over the past six years.British Columbia.

  Paul Morgan, Director

  Paul Morgan became a director of our company effective July 13,14, 2021. Mr. Morgan is a corporate / commercial lawyer located in Victoria, British Columbia and has been actively practicing in British Columbia since 2013. Mr. Morgan's legal practice has included a particular focus on various segments of the cannabis industry including, but not limited to, retailers and licensed producers of cannabis since approximately 2016.

  43

  ---

  Smoke Wallin, Director

  Smoke Wallin became a director of our company effective May 16, 2022. Mr. Wallin is the Managing Director of STS Capital Partners, the Executive Chair & Founder of Taliera, and the Executive Chair & Co-Founder of Vertical Wellness. Smoke is a highly accomplished CEO, entrepreneur, leader, board member and philanthropist with leadership across the consumer products, beverage, cannabis, hospitality, health & wellness, distribution, M&A, and technology industries. Smoke is Co-Founder & Director of DignityMoves.Org created to end unsheltered street homelessness in our communities by building Interim Supportive Housing with rapid, cost-effective, scalable solutions. Smoke earned an MBA at Vanderbilt and a Bachelor's degree in Science at Cornell.

  Family Relationships

  There are no family relationships between any of our directors and senior management.

  B. Compensation

  The following table sets forth all direct and indirect compensation paid, payable, awarded, granted, given or otherwise provided, directly or indirectly, by our company or any subsidiary thereof to members of our management and directors of our company, in any capacity, including, for greater certainty, all plan and non-plan compensation, direct and indirect pay, remuneration, economic or financial award, reward, benefit, gift or perquisite paid, payable, awarded, granted, given or otherwise provided to the members of our management or directors of our company for services provided and for services to be provided, directly or indirectly, to our company or any subsidiary thereof for the years ended December 31, 20212022 and 2020,2021, other than stock options and other compensation securities:

  3744

  ---

  Table of Compensation Excluding Compensation Securities
  Name and position	Year	Salary, consulting fee, retainer or commission	Bonus	Committee or meeting fees	Value of perquisites1	Value of all other compensation	Total compensation
  		$	$	$	$	$	$
  Andrew Hale2 Former Chief Executive Officer, President and Director	2021 2020	134,666 180,091	- -	- -	- -	- -	134,666 180,091
  Stephen Brohman3 Former Chief Financial Officer, Corporate Secretary and Director	2021 2020	61,0914 150,9004	- -	- -	- -	- -	61,091 150,900
  Blaine Blaney5 Former Chief Financial Officer and Director	2021 2020	- -	- -	- -	- -	- -	- -
  Georges Routhier6 Director	2021 2020	- 2,5007	- -	- -	- -	- -	- 2,5007
  Michael Forbes8 Chief Executive Officer, President and Director	2021 2020	40,0009 -	- -	- -	- -	- -	40,0009 -
  Donald Dinsmore10 Former Chief Operating Officer	2021 2020	122,535 -	50,000 -	- -	- -	- -	172,535 -
  Oliver Foeste11 Chief Financial Officer	2021 2020	74,51812 -	- -	- -	- -	- -	74,51812 -
  Paul Morgan13 Director	2021 2020	- -	- -	- -	- -	- -	- -

  Table of Compensation Excluding Compensation Securities
  Name and position	Year	Salary, consulting fee, retainer or commission	Bonus	Committee or meeting fees	Value of perquisites1	Value of all other compensation	Total compensation
  		$	$	$	$	$	$
  Andrew Hale2 Former Chief Executive Officer, President and Director	2022 2021	- 134,666	- -	- -	- -	- -	- 134,666
  Stephen Brohman3 Former Chief Financial Officer, Corporate Secretary and Director	2022 2021	- 61,0914	- -	- -	- -	- -	- 61,091
  Georges Routhier5 Former Director	2022 2021	2,0006 -	- -	- -	- -	- -	2,000 -
  Michael Forbes7 Chief Executive Officer, President and Director	2022 2021	120,0008 40,0008	- -	- -	- -	7,3508 -	127,350 40,000
  Donald Dinsmore9 Former Chief Operating Officer	2022 2021	102,705 122,535	- 50,000	- -	- -	- -	102,705 172,535
  Oliver Foeste10 Former Chief Financial Officer	2022 2021	286,53911 74,51811	- -	- -	- -	- -	286,539 74,518
  Paul Morgan12 Director	2022 2021	- -	- -	- -	- -	- -	- -
  Smoke Wallin13 Director	2022 2021	- -	- -	- -	- -	- -	- -
  Lachlan McLeod14 Chief Financial Officer	2022 2021	- -	- -	- -	- -	- -	- -

  Notes:

  ¹ "Perquisites" include perquisites provided to an officer or director that are not generally available to all employees and that, in aggregate, are: (a) C$15,000, if the officer or director's total salary for the financial year is C$150,000 or less, (b) 10% of the officer or director's salary for the financial year if the officer or director's total salary for the financial year is greater than C$150,000 but less than C$500,000, or (c) C$50,000 if the officer or director's total salary for the financial year is C$500,000 or greater.

  ² Andrew Hale was appointed Chief Executive Officer, President and a director of our company on December 19, 2019. Mr. Hale resigned from all positions with our company on February 26,March 1, 2021.

  ³ Stephen Brohman was appointed as a director of our company on September 2, 2014, and Chief Financial Officer and Corporate Secretary of our company on December 19, 2019. Mr. Brohman resigned on July 13, 2021.

  ⁴ We were charged by Donaldson Brohman Martin CPA Inc., a firm in which Mr. Brohman is a principal, for accounting and tax services, in the amount of $61,091 in 2021 and $150,900 in 2020.

  ⁵ Blaine Baily was appointed Chief Financial Officer of our company on June 21, 2005, Secretary of our company on April 5, 2007, and a director of our company on February 3, 2014. Mr. Bailey resigned as Secretary of our company on August 20, 2007, Chief Financial Officer of our company on December 19, 2019, and as a director of our company on March 26, 2021.

  38

  ---

  ⁶George Routhier was appointed as a director of our company on December 19, 2019. Mr. Routhier resigned on June 23, 2022.

  45

  ---

  ⁷⁶ We were charged by Pipedreemz Inc., a company controlled by Mr. Routhier, for consulting services, in the amount of $2,500$2,000 in 2020 and $17,500 in 2019.2022.

  ⁸⁷ Michael Forbes was appointed as Chief Executive Officer, President and a director of our company on April 29, 2021.

  ⁹⁸ We were charged by MDC Forbes Inc., a company controlled by Mr. Forbes, for consulting services, in the amount of $120,000 in 2022 and $40,000 in 2021. In addition, we were charged rent of $7,350 in 2022.

  ¹⁰⁹ Donald Dinsmore was appointed as Chief Operating Officer on April 29, 2021. Mr. Dinsmore resigned on February 22,March 24, 2022.

  ¹¹¹⁰ Oliver Foeste was appointed as former Chief Financial Officer of our company onfrom April 29, 2021.2021 up to January 1, 2023.

  ¹²¹¹ We were charged by Invictus Accounting Group LLP, a company controlled by Mr. Foeste, for consulting services, in the amount of $286,539 in 2022 and $74,518 in 2021.

  ¹³¹² Paul Morgan was appointed as a director of our company on July 14, 2021.

  ¹³Smoke Wallin was appointed as a director of our company on May 16, 2022.

  ¹⁴Lachlan McLeod was appointed as the Chief Financial Officer of our company on January 1, 2023. He is an employee of Fehr & Associates CPA.

  Employment, Consulting and Management Agreements

  Other than as set out herein, we do not have any employment, consulting or management agreements or arrangements with any of our directors or senior management.

  Stephen Brohman, Former Chief Financial Officer and Director

  Donaldson Brohman Martin, CPA Inc. ("DBM CPA"), Chartered Professional Accountants, provided accounting services to our company during the year ended December 31, 2021. Our former Chief Financial Officer and director, Stephen Brohman, is a principal of DBM CPA.

  Andrew Hale, Former Chief Executive Officer and Director

  Our former Chief Executive Officer and director, Andrew Hale received a fee of $180,000 per annum for providing services as Chief Executive Officer of our company. Mr. Hale resigned as our Chief Executive Officer and director effective February 26,March 1, 2021.

  Michael Forbes, Chief Executive Officer and Director

  Michael Forbes is a Director and the Company's President and CEO. He was appointed on April 29, 2021 and is the owner of MDC Forbes, which provides CEO and Corporate Secretary services to the Company.

  Oliver Foeste, Former Chief Financial Officer

  Invictus Accounting Group LLP. ("Invictus"), provided accounting, financial reporting and CFO services to our company during the year ended December 31, 2022 and 2021. HeOliver Foeste was appointed on July 13, 2021 and is the founder and Managing Partner of Invictus Accounting Group LLP.

  Lachlan McLeod, Chief Financial Officer

  Fehr & Associates CPA ("F&A"), provided accounting, financial reporting and CFO services to our company starting on January 1, 2023. Mr. McLeod was appointed as Chief Financial Officer on January 1, 2023 and is an employee of F&A.

  46

  ---

  Benefits Upon Termination

  We have no contract, agreement, plan or arrangement, whether written or unwritten, that provides for benefits to our directors or members of our management upon termination of employment of our directors or members of our management.

  39

  ---

  Stock Options and Other Compensation Securities

  The following table sets out all compensation securities granted or issued to members of our management and directors of our company during the year ended December 31, 20212022 for services provided, or to be provided, directly or indirectly, to our company or any subsidiary thereof:

  Compensation Securities
  Name and position	Type of compensation security	Number of Compensation Securities/Number of Underlying Securities /Percentage of Class	Date of Issue or Grant	Issue, Conversion or Exercise Price	Closing Price of Security or Underlying Security on Date of Grant	Closing Price of Security or Underlying Security at Year End	Expiry Date
  		#		$	$	$
  Andrew Hale Former Chief Executive Officer, President and Director	Stock options	666,666 / 666,666 / 18.0%	January 30, 2020	1.35	1.35	0.89	January 30, 2025
  	Stock options	33,333 / 33,333 / 1.0%	August 4, 2021	1.35	0.86	0.89	August 5, 2026
  Georges Routhier Director	Stock options	83,333 / 83,333 / 2.2%	January 30, 2020	1.35	1.35	0.89	January 30, 2025
  	Stock options	33,333 / 33,333 / 1.0%	August 4, 2020	2.34	2.34	0.89	August 4, 2025
  Michael Forbes Chief Executive Officer, President and Director	Stock options	300,000 / 300,000 / 8.1%	October 25, 2021	1.06	1.07	0.89	October 25, 2026
  Donald Dinsmore Former Chief Operating Officer	Stock options	166,667 / 166,667 / 4.5%	January 30, 2020	1.35	1.35	0.89	January 30, 2025
  	Stock options	66,667 / 66,667 / 1.8%	August 4, 2020	2.34	2.34	0.89	August 4, 2025
  Oliver Foeste Chief Financial Officer	Stock options	300,000 / 300,000 / 8.1%	October 25, 2021	1.06	1.07	0.89	October 25, 2026
  Paul Morgan Director	Stock options	300,000 / 300,000 / 8.1%	October 25, 2021	1.06	1.07	0.89	October 25, 2026

  Compensation Securities
  Name and position	Type of compensation security	Number of Compensation Securities/Number of Underlying Securities /Percentage of Class	Date of Issue or Grant	Issue, Conversion or Exercise Price	Closing Price of Security or Underlying Security on Date of Grant	Closing Price of Security or Underlying Security at Year End	Expiry Date
  		#		$	$	$
  Smoke Wallin Director	Stock options	300,000 / 300,000 / 8.2%	August 19, 2022	0.75	0.63	0.25	August 19, 2027

  Pension, Retirement or Similar Benefits

  We have not set aside or accrued any amounts to provide pension, retirement or similar benefits for our directors or members of our management during the year ended December 31, 2020.2022.

  40

  ---

  C. Board Practices

  Term of Office

  Each director of our company holds office until the next annual general meeting of our company or until his successor is elected or appointed, unless his office is earlier vacated in accordance with the articles of our company or the provisions of the Business Corporations Act (British Columbia). Each officer of our company is appointed to serve at the discretion of our board of directors.

  Committees

  We have one committee: the audit committee.

  Audit Committee

  We have an audit committee comprised of Michael Forbes, who also serves as the Chief Executive Officer, and George Routhier,Smoke Wallin and Paul Morgan, both of whom are independent directors.

  We have adopted a charter for our audit committee. According to our audit committee charter, the mandate of our audit committee is to assist our board of directors in fulfilling its financial oversight responsibilities. According to our audit committee charter, our audit committee will review and consider, in consultation with our auditors, the financial reporting process, the system of internal control over financial reporting and the audit process. In performing its duties, our audit committee will maintain effective working relationships with our board of directors, management and external auditors. To effectively perform his or her role, each committee member must obtain an understanding of the principal responsibilities of committee membership as well as our company's business, operations and risks.

  47

  ---

  Our audit committee has roles and responsibilities including:

  •● being directly responsible for overseeing the work of external auditors in preparing or issuing the auditor's report, including the resolution of disagreements between management and the external auditors regarding financial reporting and audit scope or procedures;

  •● considering whether controls are in place over annual and interim financial reporting as well as controls over assets, transactions and the creation of obligations, commitments and liabilities of our company;

  •● reviewing the financial statements and financial information of our company prior to their release to the public; and

  •● considering and pre-approving any non-audit services (being services other than services rendered for the audit and review of the financial statements or services that are normally provided by the external auditor in connection with statutory and regulatory filings or engagements) which are proposed to be provided by the external auditors to our company or any subsidiary of our company.

  Compensation Committee

  We do not have a separately constituted compensation or remuneration committee. Our entire board of directors acts as the compensation committee. Our board of directors is solely responsible for determining the compensation to be paid to our executive officers and evaluating their performance. In addition, our board of directors reviews annually the total compensation package of each of our executives on an individual basis.

  Our board of directors has not adopted any specific policies or objective for determining the amount or extent of compensation for directors or officers. There is no policy or target regarding allocation between cash and non-cash elements of our compensation program.

  D. Employees

  As of December 31, 20212022 and 2020,2021, we had 2263 and 2722 employees, respectively. Our employees are not members of a labor union.

  Our workforce is based out of our corporate office and Facility in Langley, British Columbia, Canada.

  41

  ---

  The breakdown of full-time employees by main category of activity and geographic location, as at December 31, 20212022 is as follows:

  Activity	Number of Full-Time Employees	Location
  Research & Development	01	Langley, British Columbia, Canada
  Production	1235	Langley, British Columbia, Canada
  Sales & Marketing	68	Langley, British Columbia, Canada
  General & Administration	318	Langley, British Columbia, Canada
  Executives	1	Langley, British Columbia, Canada

  48

  ---

  E. Share Ownership

  As of December 31, 2021,2022, our directors and management beneficially owned the following common shares and options of our company:

  Name and Office Held	Number of Common Shares Owned and Percent of Total Outstanding Common Shares		Common Shares that the individual has the right to acquire within 60 days
  	# of Shares	% of Class1	Stock Options	Warrants	Convertible Debentures
  Michael Forbes Chief Executive Officer and Director	1,256,8601,288,198 2	1.91%2.3%	300,0005	-	-
  Oliver Foeste Former Chief Financial Officer	-	-	300,0004	-	-
  Lachlan McLeod Chief Financial Officer	-	*	300,0006	-	-
  Donald Dinsmore Former Chief Operating Officer	-	*	233,3343	-	-
  Paul Morgan Director	-	-	300,00053	-	-
  Georges RouthierSmoke Wallin Director	-	*	116,6664	-	300,0006	-	-

  * denotes less than 1% of class of shares owned.

  Notes:

  ¹ Based on 65,970,54755,970,547 common shares of our company issued and outstanding as at December 31, 2021.2022.

  ² These common shares are held by MDC Forbes, a private company owned by Mr. Forbes.

  ³ Consists of 166,667300,000 stock options exercisable at a price of $1.35$1.06 per share, for a period expiring on January 30, 2025, and 66,667October 25, 2026.

  ⁴Consists of 300,000 stock options exercisable at a price of $2.34$1.06 per share, for a period expiring on August 4, 2025.

  ⁴Consists of 83,333October 25, 2026. These stock options exercisable at $1.35 per share, forare held by 1180777 B.C. Ltd, a period expiring on January 30, 2025, and 33,333 stock options exercisable at a price of $2.34 for a period expiring on August 4, 2025.private company influenced by Mr. Foeste.

  ⁵ Consists of 300,000 stock options exercisable at a price of $1.06 per share, for a period expiring on October 25, 2026.

  ⁶ Consists of 300,000 stock options exercisable at a price of $1.06$0.75 per share, for a period expiring on October 25, 2026.  These stock options are held by 1180777 B.C.Ltd, a private company influenced by Mr. Foeste.August 19, 2027.

  Stock Option Plan

  We have a stock option plan, which is a "rolling" stock option plan whereby a maximum of 10% of the issued shares of our company, from time to time, may be reserved for issuance pursuant to the exercise of options. The principal purposes of our stock option plan are to provide our company with the advantages of the incentive inherent in share ownership on the part of directors, employees, consultants of our company and our subsidiaries responsible for the continued success of our company and subsidiaries; to create in such persons a proprietary interest in, and a greater concern for, the welfare and success of our company and subsidiaries; to encourage such persons to remain with our company and subsidiaries; and to attract new directors, employees and consultants to our company and our subsidiaries.

  42

  ---

  Item 7.  Major Shareholders and Related Party Transactions

  A. Major Shareholders

  To the best of our knowledge, there are no shareholders that are beneficial owners of 5% or more of our common shares.

  B. Related Party Transactions

  Other than as disclosed below, since the beginning of our preceding three financial years ended December 31, 20212022 there have been no transactions or loans between our company and:

  (a) enterprises that directly or indirectly through one or more intermediaries, control or are controlled by, or are under common control with, our company;

  (b) associates, meaning unconsolidated enterprises in which we have a significant influence or which have significant influence over our company;

  (c) individuals owning, directly or indirectly, an interest in the voting power of our company that gives them significant influence over our company, and close members of any such individual's family (close members of an individual's family are those that may be expected to influence, or be influenced by, that person in their dealings with our company);

  49

  ---

  (d) key management personnel, that is, those persons having authority and responsibility for planning, directing and controlling the activities of our company, including directors and senior management of our company and close members of such individuals' families; and

  (e) enterprises in which a substantial interest in the voting power is owned, directly or indirectly, by any person described in (c) or (d) or over which such a person is able to exercise significant influence, including enterprises owned by directors or major shareholders of our company and enterprises that have a member of key management in common with our company.

  During the year ended December 31, 2021,2022, we granted the stock options to the following people who were management personnel or directors as of the date of grant or who are currently management personnel or directors:

  Granted to	Grant date	Expiry date		Exercise price			Stock options granted
  				$			#
  Andrew Hale	August 4, 2021	August 4, 2026		1.35			33,333
  Paul Morgan	October 25,2021	October 25,2026		1.06			300,000
  Michael Forbes	October 25,2021	October 25,2026		1.06			300,000
  1180777 B.C. Ltd	October 25,2021	October 25,2026		1.06			300,000

  43

  ---

  Granted to	Grant date	Expiry date		Exercise price			Stock options granted
  				$			#
  Smoke Wallin	August 19, 2022	August 19, 2027		0.75			300,000

  The aggregate value of transactions and outstanding balances with key management personnel and directors and entities over which they have control or significant influence were as follows:

  		Transactions for the years ended December 31,						Balances outstanding December 31,						Transactions for the years ended December 31,						Balances outstanding December 31,
  		2021			2020			2021			2020			2022			2021			2022			2021
  		$			$			$			$			$			$			$			$
  Andrew Hale		134,666			180,091			-			-			-			134,666			-			-
  DBM CPA		61,091			150,900			-			12,915			-			61,091			-			-
  Donald Dinsmore		172,535			-			50,000			-			102,705			172,535			-			50,000
  Invictus Accounting Group LLP		74,518			-			8,933			-			286,539			74,518			13,884			8,933
  MDC Forbes		40,000			-			11,688			-			127,350			40,000			62,427			11,688
  Michael Forbes														-			-			20,000
  Pipedreemz		-			2,500			-			-			2,000			-			3,350			-
  		482,810			333,491			70,621			12,915			518,594			482,810			99,661			70,621

  All related party balances are unsecured and are due within thirty days without interest.interest and incurred in the normal course of business.

  The above transactions with the key management personnel and directors are included in operating expenses as follows:

  Donaldson Brohman Martin CPA Inc.

  The amounts consist of the professional fees charged by DBM CPA for the accounting and tax services of Stephen Brohman, our former Chief Financial Officer and director. Mr. Brohman is a principal of DBM CPA, a firm in which he has significant influence.

  Andrew Hale

  The amounts consist of charges by Andrew Hale, our former Chief Executive Officer and director, for salaries paid.

  Pipedreemz Inc.

  The amounts consist of the consulting fees charged to our company by Pipedreemz Inc. for advisory services to our company. George Routhier, a director of our company, is the owner of Pipedreemz Inc.

  50

  ---

  Invictus Accounting Group LLP

  The amounts consist of the professional fees charged by Invictus Accounting Group LLP for the accounting and tax services of Oliver Foeste, our former Chief Financial Officer. Mr. Foeste is the Managing Partner of Invictus Accounting Group LLP, a firm in which he has significant influence.

  Cannabis Supply agreement with Sitka Weed Works Inc

  On October 7, 2021 the Company entered into a supply and purchase agreement with Sitka Weed Works. This is a related party transaction because Michael Forbes is a director and controlling shareholder of Sitka Weed Works Inc. Under the terms of the agreement, Sitka Weed Works Inc. will supply cannabis products to the Company on a non-exclusive basis and the Company shall purchase the cannabis products on a non-exclusive basis. These cannabis products will be used by the Company as raw materials for its production lines.

  C. Interests of Experts and Counsel

  Not applicable.

  44

  ---

  Item 8.  Financial Information

  A. Consolidated Statements and Other Financial Information

  The consolidated financial statements of the Company included with this annual report on Form 20-F have been prepared in compliance with International Financial Reporting Standards, as adopted by the International Accounting Standards Board. See "Item 18. Financial Statements".

  Export Sales

  None.

  Legal Proceedings

  None.

  Dividends

  We have not declared any dividends since our inception and do not anticipate that we will do so in the foreseeable future. We currently intend to retain future earnings, if any, to finance the development of our business. Any future payment of dividends or distributions will be determined by our board of directors on the basis of our earnings, financial requirements and other relevant factors.

  B. Significant Changes

  The management of our company is not aware of any significant changes since the date of our most recent annual financial statements that have not been disclosed elsewhere in this annual report on Form 20-F.

  Item 9. The Offer and Listing.

  A. Offer and Listing Details

  Principal Market

  Our common shares are listed for trading on the Canadian Securities Exchange under the symbol "XTRX". Our common shares also trade on the Frankfurt Stock Exchange under the symbol "D2EP".

  Our common shares are in registered form and the transfer of our common shares is managed by our transfer agent, National Securities Administrators Ltd., located at Suite 702, 777 Hornby Street, Vancouver, British Columbia V6Z 1S4, Canada.

  51

  ---

  B. Plan of Distribution

  Not applicable.

  C. Markets

  See "Item 9.A Offer Listing and Details".

  On July 15, 2013, the Securities and Exchange Commission issued an order pursuant to Section 12(j) of the Securities Exchange Act of 1934 (the "Exchange Act") revoking registration of common shares of Gulfside Industries Ltd. (n/k/a Consolidated Gulfside Resources, Ltd.) registered pursuant to Section 12(g) of the Exchange Act. Gulfside Industries Ltd. was a former name of our company at that time. The registration was revoked because we were delinquent in our periodic filings with the Securities and Exchange Commission having not filed any periodic reports since we filed a Form 10-Q for the period ended March 31, 1995.

  45

  ---

  We may seek a broker-dealer to have quotations for our common shares entered on the OTC Link alternative trading system maintained by OTC Markets Group Inc. There is no assurance that our common shares will trade on the OTC Link or on any other market or exchange in the United States, or if our common shares are traded on a market or exchange in the United States, that a liquid public market for those shares will materialize. There is currently no public market in the United States for our common shares and investors in the United States may have difficulty reselling our common shares.

  D. Selling Shareholders

  Not applicable.

  E. Dilution

  Not applicable.

  F. Expenses of the Issue

  Not applicable.

  Item 10.  Additional Information.

  A. Share Capital

  We are authorized to issue an unlimited number of common shares without par value.

  All of our common shares issued and outstanding were fully paid and non-assessable. There are no shares not representing capital. Our Company or subsidiaries do not own any shares of our company.

  On December 31, 2021,2022, we had 65,970,54755,970,547 common shares outstanding, subsequent tooutstanding. During the issuance of 2,513,720year ended December 31, 2022, we cancelled 10,000,000 common shares forrelated to the acquisition of PerceiveMD, 20,000,000 common shares for the acquisition of 1204581 and 122,727 common shares from a non-brokered private placement.

  1204581. Subsequent to the closing of the acquisition, the Company renegotiated terms of the acquisition with the former shareholders of Phyto BrandCo due to certain conditions in the acquisition agreement not being met. It was resolved that the consideration be amended from $24,000,000 to $12,000,000 by a voluntary return to treasury of 10,000,000 common shares.

  All of ourOn December 31, 2021, we had 65,970,547 common shares outstanding. During the year ended December 31, 2021, we issued of 2,513,720 common shares for the acquisition of PerceiveMD, 20,000,000 common shares for the acquisition of 1204581 and outstanding were fully paid and non-assessable. There are no122,727 common shares not representing capital. Our Company or subsidiaries do not own any shares of our company.from a non-brokered private placement.

  On December 31, 2020, we had 43,334,100 common shares outstanding.

  On December 31, 2019, we had 36,228,941 common shares issued and outstanding. During the year ended December 31, 2020, we issued a total of 7,105,159 common shares so thatshares.

  On December 31, 2019, we had 43,334,10036,228,941 common shares issued and outstanding as at December 31, 2020.outstanding.

  More than 10% of our capital has not been paid for with assets other than cash within the past five years.

  4652

  ---

  Warrants

  As at December 31, 2022, we had the following outstanding warrants to purchase our common shares:

  Expiry date		Exercise price			Warrants outstanding and exercisable
  		$			#
  October 18, 2023		1.75			122,727
  Total outstanding					122,727

  As at December 31, 2021, we had the following outstanding warrants to purchase our common shares:

  Expiry date		Exercise price			Warrants outstanding and exercisable
  		$			#
  January 17, 2022		2.25			189,934
  January 27, 2022		2.25			266,760
  July 10, 2022		2.25			200,589
  July 13, 2022		1.50			3,882,667
  July 16, 2022		2.25			759,605
  July 28, 2022		2.25			953,564
  August 5, 2022		2.25			161,688
  December 19, 2022		1.80			1,921,185
  October 18, 2023		1.75			122,727
  Total outstanding					8,458,719

  Stock Options

  As at December 31, 2020,2022, we had the following outstanding warrantsstock options to purchase our common shares:

  Expiry date	Exercise price	Warrants outstanding and exercisable
  	$	#
  January 17, 2022	2.25	189,934
  January 27, 2022	2.25	266,760
  July 10, 2022	2.25	200,589
  July 13, 2022	1.50	3,882,667
  July 16, 2022	2.25	759,605
  July 28, 2022	2.25	953,564
  August 5, 2022	2.25	161,688
  December 19, 2022	1.80	1,921,185
  Total outstanding		8,335,992

  Stock Options

  Expiry date		Exercise price			Stock options outstanding and exercisable
  		$			#
  January 30, 2025		1.35			1,583,334
  August 5, 2025		2.34			683,333
  August 5, 2026		1.35			33,333
  October 25, 2026		1.06			900,000
  October 28, 2026		0.95			165,000
  August 19, 2027		0.75			300,000
  Total outstanding					3,665,000

  As at December 31, 2021, we had the following outstanding stock options to purchase our common shares:

  Expiry date		Exercise price			Stock options outstanding and exercisable
  		$			#
  June 1, 2022		1.35			66,667
  January 30, 2025		1.35			1,750,001
  August 5, 2025		2.34			750,000
  August 4, 2026		1.35			33,333
  October 25, 2026		1.06			900,000
  October 28, 2026		0.95			215,000
  Total outstanding					3,715,001

  As at December 31, 2020, we had the following outstanding stock options to purchase our common shares:

  Expiry date	Exercise price	Stock options outstanding and exercisable
  	$	#
  June 1, 2022	1.35	66,667
  January 30, 2025	1.35	2,483,333
  August 5, 2025	2.34	1,616,667
  Total outstanding		4,166,667

  4753

  ---

  Other Convertible Obligations or Other Outstanding Equity-Linked Securities, or Subscription Rights

  Other than the warrants and stock options described above, as at December 31, 20212022 and 2020,2021, we had no outstanding convertible obligations or other outstanding equity-linked securities.

  Issuances of Securities

  During the last three years, we have issued the following securities:

  Since the Fiscal Year Ended December 31, 20212022

  On January 6, 2023, 1,300,000 shares were released from escrow.

  On August 19, 2022, we granted 300,000 stock options to a certain director for the purchase of up to 300,000 common shares at a price of $0.75 per share. Each stock option is exercisable for a period of five years.

  On July 6, 2022, 1,300,000 shares were released from escrow

  On April 29, 2022, 10,000,000 common shares related to the amended agreement between the Company and former owners of Phyto BrandCo were returned to treasury and cancelled for no consideration

  On January 6, 2022, 1,300,000 shares were released from escrow.

  Fiscal Year Ended December 31, 2021

  On October 28, 2021, we granted an aggregate of 215,000 stock options to certain employees and a consultant for the purchase of up to 215,000 common shares at a price of $0.95 per share. Each stock option is exercisable for a period of five years.

  On October 25, 2021, we granted an aggregate of 900,000 stock options to certain directors and officers for the purpose of up to 900,000 common shares at a price of $1.06 per share. Each stock option is exercisable for a period of five years.

  On October 18, 2021, we completed a non-brokered private placement whereby we issued 122,727 units at a price of $1.10 per unit for gross proceeds of $135,000. Each unit was comprised of one common share and one transferrable common share purchase warrant with each warrant entitling the holder thereof to acquire one common share at a price of $1.75 per share for two years from the date of the closing. The warrants are subject to an acceleration provision whereby if the daily closing price of the common shares as quoted on the Canadian Securities Exchange closes at or above $2 per share for 50 consecutive trading days, then we may accelerate the expiration date of the warrants to the date that is 30 trading days from the date that notice of such acceleration is given via news release. From and after the new accelerated expiration date, no warrants may be exercised, and all unexercised warrants will be void.

  On September 17, 2021, we issued an aggregate of 20,000,000 common shares to the former shareholders of 1204581 in consideration for their respective shares of 1204581. Subsequent to the closing of the acquisition, the Company renegotiated terms of the acquisition with the former shareholders of Phyto BrandCo due to certain conditions in the acquisition agreement not being met. It was resolved that the consideration be amended from $24,000,000 to $12,000,000 by a voluntary return to treasury of 10,000,000 common shares.

  On August 31, 2021, we issued an aggregate of 2,513,720 common shares to the former shareholders of PerceiveMD in consideration for their respective shares of PerceiveMD.

  On August 4, 2021, we granted an aggregate of 33,333 stock options to a consultant for the purchase of up to 33,333 common shares at a price of $1.35 per share. Each stock option is exercisable for a period of five years.

  On April 9, 2021, the Company consolidated its issued share capital on a ratio of three (3) old common shares for every one (1) new post-consolidated common share. All current and comparative references to the number of common shares, weighted average number of common shares, loss per share, stock options and warrants have been restated to give effect to this share consolidation.

  54

  ---

  Fiscal Year Ended December 31, 2020

  On August 5, 2020, we issued 161,688 units on conversion of $200,000 of principal and $18,279 of accrued interest of the convertible debenture. Each unit consisted of one common share of our company and one share purchase warrant exercisable at $2.25 for two years from the date of conversion. No value was attributed to the warrant component of the units issued.

  On August 5, 2020, the Company granted 1,616,667 stock options with exercise price of $2.34 to certain Directors, Officers, employees, and consultants. The options expire in five years from the date of grant and vest immediately. The fair value of these options was $2,813,800 ($1.74 per option) and was recognized as a share-based payments.

  48

  ---

  On July 28, 2020, we issued 953,564 units on conversion of $1,182,000 of principal and $105,311 of accrued interest of the convertible debenture. Each unit consisted of one common share of our company and one share purchase warrant exercisable at $2.25 for two years from the date of conversion. No value was attributed to the warrant component of the units issued.

  On July 16, 2020, we issued 759,605 units on conversion of $945,000 of principal and $80,467 of accrued interest of the convertible debenture. Each unit consisted of one common share of our company and one share purchase warrant exercisable at $2.25 for two years from the date of conversion. No value was attributed to the warrant component of the units issued.

  On July 13, 2020, we completed a non-brokered private placement whereby 3,882,667 units were issued at a price of $0.90 per unit for gross proceeds of $3,494,400. Each unit consisted of one common share and one common share purchase warrant with each warrant exercisable into one common share at an exercise price of $1.50 until July 13, 2022. Additionally, we settled services and outstanding indebtedness of $543,715 through the issuance of 647,385 common shares at a fair value price of $0.84 per share.

  On July 10, 2020, we issued 200,589 units on conversion of $250,000 of principal and $20,795 of accrued interest of the convertible debenture. Each unit consisted of one common share of our company and one share purchase warrant exercisable at $2.25 for two years from the date of conversion. No value was attributed to the warrant component of the units issuedissued.

  On June 1, 2020, the Company granted 66,667 stock options with exercise price of $1.35 to an employee. The options expire two years from the date of grant and vest immediately. The fair value of these options was $22,200 ($0.33 per option) and was recognized as share-based payments.

  On January 30, 2020, the Company granted 2,523,333 stock options with exercise price of $1.35 to certain Directors, Officers, employees, and consultants. The options expire in five years from the date of grant and vest immediately. The fair value of these options was $2,537,300 ($1.02 per option) and was recognized as a share-based payments.

  On January 27, 2020, we issued 266,760 units on conversion of $350,000 of principal and $10,126 of accrued interest of the convertible debenture. Each unit consisted of one common share of our company and one share purchase warrant exercisable at $2.25 for two years from the date of conversion. No value was attributed to the warrant component of the units issued.

  On January 17, 2020, we issued 189,934 units on conversion of $250,000 of principal and $6,411 of accrued interest of the convertible debenture. Each unit consisted of one common share of our company and one share purchase warrant exercisable at $2.25 for two years from the date of conversion. No value was attributed to the warrant component of the units issued.

  During the year ended December 31, 2020, we issued 42,967 common shares related to the exercise of 42,967 warrants at an exercise price of $1.80 per share.

  Fiscal Year from June 1, 2019 to December 31, 201955

  ---

  On December 20, 2019, we completed a non-brokered private placement whereby 1,964,152 units were issued at a price of $1.35 per unit for gross proceeds of $2,651,605.  Each unit consisted of one common share and one common share purchase warrant with each warrant exercisable into one common share at an exercise price of $0.60 for three years from the date of closing December 20, 2022.

  On December 20, 2019, we issued 7,218,678 common shares at a price of $0.15 per share to the shareholders of Arrowstar as consideration for the RTO of Arrowstar by Adastra.

  B. Memorandum and Articles of Association

  Our Company was incorporated on October 14, 1987 under the laws of the Province of British Columbia. Our corporation number is BC0334777. Our Company is governed by the Business Corporations Act (British Columbia) (the "BCBCA"), and its Notice of Articles (which sets forth the name and authorized share structure of our company), and its Articles (which sets forth rules for our company's conduct) are described below.

  49

  ---

  Objects and Purposes

  Our Articles do not contain, and are not required under the laws of British Columbia, to contain a description of the our company's objects or purposes. There are no restrictions in our Notice of Articles or Articles on the business that we may carry on.

  Powers of Directors

  Our directors are responsible for managing and supervising the management of the affairs and business of our Company and have authority to exercise all such powers of our company that are not required by the BCBCA or our Articles, to be exercised by our shareholders.

  Each director holds office until our next annual general meeting or until he or she is removed, dies or his or her office is earlier vacated in accordance with our Articles or with the provisions of the BCBCA. A director appointed or elected to fill a vacancy on our board holds office until our next annual general meeting. Under our Articles, a director is not required to hold any shares of our company to qualify as a director or officer.

  The directors are entitled to the remuneration, if any, for acting as directors as the directors may from time to time determine. If the directors so decide, the remuneration of the directors will be determined by the shareholders. That remuneration may be in addition to any salary or other remuneration paid to a director in such director's capacity as an officer or employee of our company. Our Articles do not contain any requirements with respect to the determination of remuneration of the directors in the absence of an independent quorum.

  Pursuant to our Articles, any director that holds a material interest in any contract or transaction that is material to our company (a "disclosable interest") must disclose that interest to the board, and abstain from voting to approve such contract or transaction, unless all of our directors have a disclosable interest in that contract or transaction, in which case any or all of the directors may vote. Interested directors may, however, be counted for purposes of determining if a quorum is present at a meeting of the directors at which such contract or transaction is to be considered. Directors or officers with a disclosable interest in a contract or transaction is not liable to account for any profits if the disclosable interest is disclosed and the transaction is approved by the disinterested directors or by our shareholders by way of a special resolution approved by a 2/3 majority of the votes cast. Transactions or contracts in which a director or officer has a disclosable interest are not invalid or void as a result of the interest, even if the necessary disclosures are not made or the approvals are not obtained.

  Our Articles provide that our company, if authorized by its directors, may:

  •● borrow money in the manner and amount, on the security, from the sources and on the terms and conditions that the directors consider appropriate;

  •● issue bonds, debentures and other debt obligations either outright or as security for any liability or obligation of our company or any other person and at such discounts or premiums and on such other terms as the directors consider appropriate;

  •● guarantee the repayment of money by any other person or the performance of any obligation of any other person; and

  •● mortgage, charge, whether by way of specific or floating charge, grant a security interest in, or give other security on, the whole or any part of the present and future assets and undertaking of our company.

  Our Articles and the BCBCA do not provide for any mandatory retirement age for directors.

  56

  ---

  Common Shares

  We are authorized to issue an unlimited number of common shares without par value. The holders of our common shares are entitled to vote at all meetings of our shareholders, to receive dividends if, as and when declared by our board of directors and to participate ratably in any distribution of property or assets upon the liquidation, winding-up or other dissolution of our company. Our common shares carry no pre-emptive rights, conversion or exchange rights, redemption, retraction, repurchase, sinking fund or purchase fund provisions. There are no provisions requiring the holders of our common shares to contribute additional capital and there are no restrictions on the issuance of additional securities by our company. There are no restrictions on the repurchase or redemption of our common shares, or the declaration of any dividends or distributions, by our company except to the extent that any such repurchase, redemption, dividend or distribution would render our company insolvent pursuant to the BCBCA.

  50

  ---

  Any alteration or variation to the special rights and restrictions attached to any class or series of any of our issued and outstanding shares will require approval by a separate resolution passed by a 2/3 of the holders of that class or series.

  Meetings of the Shareholders

  Meetings of our shareholders may be located anywhere in British Columbia or, if approved by the Issuer's directors, any location outside of British Columbia.

  Our Articles and the BCBCA provide that our annual meetings of shareholders must be held at least once in each calendar year and not more than 15 months after the last annual general meeting at such time and place as our directors may determine.

  Our directors may, at any time, call a meeting of shareholders. Under the BCBCA, the holders of not less than 5% of the Issuer's issued shares that carry the right to vote at a meeting may requisition our directors to call a meeting of shareholders for the purposes of transacting any business that may be transacted at a general meeting.

  Shareholders entitled to vote at meetings are entitled to attend any meeting of shareholders. In addition, the directors, the president, if any, the secretary, if any, and any lawyer or auditor for the Issuer are entitled to attend any meeting of shareholders, but if any of those persons do attend a meeting of shareholders, that person is not to be counted in the quorum, and is not entitled to vote at the meeting, unless that person is a shareholder or proxy holder entitled to vote at the meeting.

  Under our Articles, the quorum for the transaction of business at a meeting of our shareholders is two persons that are, or who represent by proxy, shareholders holding at least 5% of the shares entitled to vote at the meeting.

  Limitations on Share Ownership

  There are no limitations under the BCBCA or our Articles with respect to the rights of non-Canadians to own or vote shares of our company. The Investment Canada Act (Canada) provides for the review of certain significant transactions in Canada by non-Canadians that could be injurious to national security.

  Changes in Control

  There are no provisions in our Article that would have the effect of delaying, deferring or preventing a change in control of our company, and that would operate only with respect to a merger, acquisition or corporate restructuring involving our company or our subsidiaries.

  Disclosures of Share Ownership

  There are no provisions in our Articles requiring the disclosure of an ownership interest in our shares above any threshold. In general, under applicable securities regulation in Canada, a person or company who beneficially owns, directly or indirectly, voting securities of an issuer or who exercises control or direction over voting securities of an issuer or a combination of both, carrying more than 10% of the voting rights attached to all the issuer's outstanding voting securities is an insider and must, within 10 days of becoming an insider, file a report in the required form effective the date on which the person became an insider. The report must disclose any direct or indirect beneficial ownership of, or control or direction over, securities of the reporting issuer. Additionally, securities regulation in Canada provides for the filing of a report by an insider of a reporting issuer whose holdings change, which report must be filed within five days from the day on which the change takes place.

  57

  ---

  The rules in the U.S. governing the ownership threshold above which shareholder ownership must be disclosed are more stringent than those discussed above. Section 13 of the Exchange Act imposes reporting requirements on persons who acquire beneficial ownership (as such term is defined in Rule 13d-3 under the Exchange Act) of more than 5% of a class of an equity security registered under Section 12 of the Exchange Act. In general, such persons must file, within 10 days after such acquisition, a report of beneficial ownership with the Securities and Exchange Commission containing the information prescribed by the regulations under Section 13 of the Exchange Act. This information is also required to be sent to the issuer of the securities and to each exchange where the securities are traded.

  51

  ---

  Upon the effectiveness of this annual report, United States federal securities laws will require our company to disclose, in its annual reports on Form 20-F, holders who own 5% or more of our issued and outstanding voting shares.

  C. Material Contracts

  There are no other contracts, other than those disclosed below and those entered into in the ordinary course of our business, that are material to our company and which were entered into in the last two completed fiscal years or which were entered into before the two most recently completed fiscal years but are still in effect as of the date of this annual report:

  	•	On May 14, 2019, we entered into an agreement with United Science, LLC for the purchase of various equipment necessary for our business. The total equipment costs totaled $756,900.
  	•	On March 12, 2020, we entered into a supply agreement with CannMart Labs Inc. to supply certain cannabis and marijuana extract and concentrate products to CannMart Labs. This agreement is subject to the condition that both parties receive the required approvals from Health Canada.
  	•	On April 3, 2020, we entered into a toll processing agreement with Acreage Pharms Ltd. Pursuant to this agreement, we agreed to provide standard processing services to Acreage Pharms Ltd. Standard processing, in this agreement, means altering the physical or chemical properties of cannabis and/or hemp by the use of a solvent to produce cannabis or hemp products. This agreement is subject to the condition that both parties receive the required approvals from Health Canada.
  	•	On May 6, 2020, we entered into a toll processing agreement with Muskoka Grown Ltd. Pursuant to this agreement, we agreed to provide standard processing services to Muskoka Grown Ltd. Standard processing, in this agreement, means altering the physical or chemical properties of cannabis and/or hemp by the use of a solvent to produce cannabis or hemp products. This agreement is subject to the condition that both parties receive the required approvals from Health Canada.
  	•	On June 1, 2020, we entered into a toll processing agreement with BC Hop Company Ltd. Pursuant to this agreement, we agreed to provide standard processing services to BC Hop Company Ltd. Standard processing, in this agreement, means altering the physical or chemical properties of cannabis and/or hemp by the use of a solvent to produce cannabis or hemp products. This agreement is subject to the condition that both parties receive the required approvals from Health Canada.
  	•	On August 5, 2020, we entered into an agreement with Evolved Extraction Solutions Ltd. for the purchase of various equipment necessary for our business. The total equipment costs totaled $760,440.
  	•	On August 17, 2020, we entered into a supply agreement with Pure Sunfarms Corp for cannabis products. We agreed to purchase a minimum of 6,000 Kilograms of cannabis product from Pure Sunfarms at a price of $0.20 per gram. This agreement had a term of 6 months.
  	•	On September 4, 2020, we entered into an agreement with ExtractionTek Sales LLC for the purchase of various equipment necessary for our business. The total equipment costs totaled $284,010.
  	•	On October 15, 2020, we entered into a letter of engagement with Proactive Investors Canada who agreed to provide investor relation services involving media promotion and coverage of our company. The letter of engagement contemplates a one year term and we agreed to pay Proactive $22,501 for their services.
  	•	On January 15, 2021, we entered into a toll processing agreement with SynerGenetics Bioscience Inc. Pursuant to this agreement, we agreed to provide standard processing services to SynerGenetics Bioscience Inc. Standard processing, in this agreement, means altering the physical or chemical properties of cannabis and/or hemp by the use of a solvent to produce cannabis or hemp products. This agreement is subject to the condition that both parties receive the required approvals from Health Canada.

  • On May 14, 2019, we entered into an agreement with United Science, LLC for the purchase of various equipment necessary for our business. The total equipment costs totaled $756,900.
  • On March 12, 2020, we entered into a supply agreement with CannMart Labs Inc. to supply certain cannabis and marijuana extract and concentrate products to CannMart Labs (the "Phyto Licensing Agreement"). This agreement was subject to the condition that both parties receive the required approvals from Health Canada.
  • On April 3, 2020, we entered into a toll processing agreement with Acreage Pharms Ltd. Pursuant to this agreement, we agreed to provide standard processing services to Acreage Pharms Ltd. Standard processing, in this agreement, means altering the physical or chemical properties of cannabis and/or hemp by the use of a solvent to produce cannabis or hemp products. This agreement is subject to the condition that both parties receive the required approvals from Health Canada.
  • On May 6, 2020, we entered into a toll processing agreement with Muskoka Grown Ltd. Pursuant to this agreement, we agreed to provide standard processing services to Muskoka Grown Ltd. Standard processing, in this agreement, means altering the physical or chemical properties of cannabis and/or hemp by the use of a solvent to produce cannabis or hemp products. This agreement is subject to the condition that both parties receive the required approvals from Health Canada.
  • On June 1, 2020, we entered into a toll processing agreement with BC Hop Company Ltd. Pursuant to this agreement, we agreed to provide standard processing services to BC Hop Company Ltd. Standard processing, in this agreement, means altering the physical or chemical properties of cannabis and/or hemp by the use of a solvent to produce cannabis or hemp products. This agreement is subject to the condition that both parties receive the required approvals from Health Canada.
  • On August 5, 2020, we entered into an agreement with Evolved Extraction Solutions Ltd. for the purchase of various equipment necessary for our business. The total equipment costs totaled $760,440.

  5258

  ---

  	•	On April 13, 2021, we entered into a marketing services agreement with Hybrid Financial Ltd. Hybrid Financial has agreed to assist in all aspects of a marketing campaign for our company. Hybrid Financial will, among other things, contact investment professionals and provide updates on their marketing services to garner interest in our securities. Hybrid Financial will be paid a cash sum for their services.
  	•	On June 9, 2021, we, Adastra Labs Inc. as purchaser and Phyto Extractions Inc. as guarantor, entered into a supply agreement with Pure Sunfarms Corp. Pursuant to this agreement we agreed to purchase bulk amounts of cannabis-related products from Pure Sunfarms at various price points depending on the amount of products purchased.
  	•	On August 10, 2021, we, Adastra Labs Inc. as purchaser and Adastra Holdings Ltd. as a contributor towards the purchase price, entered into a Share Purchase Agreement with Jean Paul Lim and MDC Forbes Inc. for the purchase of all of the issued and outstanding shares of Perceive MD. Pursuant to this agreement, we agreed to pay the shareholders of Perceive MD an amount of Shares equal to $2,290,000.00 as calculated on the basis of the daily volume weighted average of actual trading prices (measured in hundredths of cents) for 10 consecutive trading days immediately prior to the closing date of the acquisition.
  	•	On September 15, 2021, we, Adastra Labs Inc. as purchaser and Adastra Holdings Ltd., entered into a Share Purchase Agreement with the shareholders of 1204581 for the purchase of all the issued and outstanding shares of 1204581. Pursuant to this agreement, we agreed to pay 1204581 shareholders 20,000,000 common shares equal to $24,000,000. Subsequent to the closing of the acquisition, the Company renegotiated terms of the acquisition with the former shareholders of Phyto BrandCo due to certain conditions in the acquisition agreement not being met.  It was resolved that the consideration be amended from $24,000,000 to $12,000,000 by a voluntary return to treasury of 10,000,000 common shares.

  • On August 17, 2020, we entered into a supply agreement with Pure Sunfarms Corp for cannabis products. We agreed to purchase a minimum of 6,000 Kilograms of cannabis product from Pure Sunfarms at a price of $0.20 per gram. This agreement had a term of 6 months.
  • On September 4, 2020, we entered into an agreement with ExtractionTek Sales LLC for the purchase of various equipment necessary for our business. The total equipment costs totaled $284,010.
  • On October 15, 2020, we entered into a letter of engagement with Proactive Investors Canada who agreed to provide investor relation services involving media promotion and coverage of our company. The letter of engagement contemplates a one year term and we agreed to pay Proactive $22,501 for their services.
  • On December 4, 2020, we amended and restated the Phyto Licensing Agreement with CannMart Labs Inc. Inc. for the use of our brands in association with development, manufacture, production, promotion, marketing, packaging, distribution and sale of cannabis related products.
  • On January 15, 2021, we entered into a toll processing agreement with SynerGenetics Bioscience Inc. Pursuant to this agreement, we agreed to provide standard processing services to SynerGenetics Bioscience Inc. Standard processing, in this agreement, means altering the physical or chemical properties of cannabis and/or hemp by the use of a solvent to produce cannabis or hemp products. This agreement is subject to the condition that both parties receive the required approvals from Health Canada.
  • On April 13, 2021, we entered into a marketing services agreement with Hybrid Financial Ltd. Hybrid Financial has agreed to assist in all aspects of a marketing campaign for our company. Hybrid Financial will, among other things, contact investment professionals and provide updates on their marketing services to garner interest in our securities. Hybrid Financial will be paid a cash sum for their services.
  • On June 9, 2021, we, Adastra Labs Inc. as purchaser and Phyto Extractions Inc. as guarantor, entered into a supply agreement with Pure Sunfarms Corp. Pursuant to this agreement we agreed to purchase bulk amounts of cannabis-related products from Pure Sunfarms at various price points depending on the amount of products purchased.
  • On August 10, 2021, we, Adastra Labs Inc. as purchaser and Adastra Holdings Ltd. as a contributor towards the purchase price, entered into a Share Purchase Agreement with Jean Paul Lim and MDC Forbes Inc. for the purchase of all of the issued and outstanding shares of Perceive MD. Pursuant to this agreement, we agreed to pay the shareholders of Perceive MD an amount of Shares equal to $2,290,000.00 as calculated on the basis of the daily volume weighted average of actual trading prices (measured in hundredths of cents) for 10 consecutive trading days immediately prior to the closing date of the acquisition.
  • On September 15, 2021, we, Adastra Labs Inc. as purchaser and Adastra Holdings Ltd., entered into a Share Purchase Agreement with the shareholders of 1204581 for the purchase of all the issued and outstanding shares of 1204581. Pursuant to this agreement, we agreed to pay 1204581 shareholders 20,000,000 common shares equal to $24,000,000. Subsequent to the closing of the acquisition, the Company renegotiated terms of the acquisition with the former shareholders of Phyto BrandCo due to certain conditions in the acquisition agreement not being met. It was resolved that the consideration be amended from $24,000,000 to $12,000,000 by a voluntary return to treasury of 10,000,000 common shares.
  • On August 30, 2022, we entered into a collaboration agreement with CannMart Labs Inc. and CannMart Inc. for the right and option to terminate the amended and restated Phyto Licence Agreement subject to certain conditions.

  D. Exchange Controls

  There are no government laws, decrees or regulations in Canada that restrict the export or import of capital or that affect the remittance of dividends, interest or other payments to non-resident holders of our common shares. However, the remittance of dividends or other payments to United States residents or other non-residents of Canada may be subject to withholding taxes or may be required to be reported under the Proceeds of Crime (Money Laundering) and Terrorist Financing Act.

  59

  ---

  E. Taxation

  Certain Canadian Federal Income Tax Considerations for United States Residents

  The following is a summary of certain Canadian federal income tax considerations generally applicable to the holding and disposition of our securities acquired by a holder who, at all relevant times, (a) for the purposes of the Income Tax Act (Canada) (i) is not resident, or deemed to be resident, in Canada, (ii) deals at arm's length with us, and is not affiliated with us, (iii) holds our common shares as capital property, (iv) does not use or hold the common shares in the course of carrying on, or otherwise in connection with, a business carried on or deemed to be carried on in Canada and (v) is not a "registered non-resident insurer" or "authorized foreign bank" (each as defined in the Income Tax Act (Canada)), or other holder of special status, and (b) for the purposes of the Canada-U.S. Tax Convention (the "Tax Treaty"), is a resident of the United States, has never been a resident of Canada, does not have and has not had, at any time, a permanent establishment or fixed base in Canada, and who otherwise qualifies for the full benefits of the Tax Treaty. Holders who meet all the criteria in clauses (a) and (b) above are referred to herein as "U.S. Holders", and this summary only addresses such U.S. Holders.

  This summary does not deal with special situations, such as the particular circumstances of traders or dealers, tax exempt entities, insurers or financial institutions, or other holders of special status or in special circumstances. Such holders, and all other holders who do not meet the criteria in clauses (a) and (b) above, should consult their own tax advisors.

  This summary is based on the current provisions of the Income Tax Act (Canada), the regulations thereunder in force at the date hereof, the current provisions of the Tax Treaty, and our understanding of the administrative and assessing practices of the Canada Revenue Agency published in writing prior to the date hereof. This summary takes into account all specific proposals to amend the Income Tax Act (Canada) and regulations thereunder publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (the "Proposed Amendments") and assumes that such Proposed Amendments will be enacted in the form proposed. However, such Proposed Amendments might not be enacted in the form proposed, or at all. This summary does not otherwise take into account or anticipate any changes in law or administrative or assessing practices, whether by legislative, governmental or judicial decision or action, nor does it take into account tax laws of any province or territory of Canada or of any other jurisdiction outside Canada, which may differ significantly from those discussed in this summary.

  53

  ---

  For the purposes of the Income Tax Act (Canada), all amounts relating to the acquisition, holding or disposition of our securities must generally be expressed in Canadian dollars. Amounts denominated in United States currency generally must be converted into Canadian dollars using the rate of exchange that is acceptable to the Canada Revenue Agency.

  This summary is of a general nature only and is not intended to be, nor should it be construed to be, legal or tax advice to any particular U.S. Holder, and no representation with respect to the Canadian federal income tax consequences to any particular U.S. Holder or prospective U.S. Holder is made. This summary is not exhaustive of all Canadian federal income tax considerations. Accordingly, all prospective purchasers (including U.S. Holders as defined above) should consult with their own tax advisors for advice with respect to their own particular circumstances.

  Withholding Tax on Dividends

  Amounts paid or credited or deemed to be paid or credited as, on account or in lieu of payment of, or in satisfaction of, dividends on our common shares to a U.S. Holder will be subject to Canadian withholding tax. Under the Tax Treaty, the rate of Canadian withholding tax on dividends paid or credited by us to a U.S. Holder that beneficially owns such dividends and substantiates eligibility for the benefits of the Tax Treaty is generally 15% (unless the beneficial owner is a company that owns at least 10% of our voting stock at that time, in which case the rate of Canadian withholding tax is generally reduced to 5%).

  Dispositions

  A U.S. Holder will not be subject to tax under the Income Tax Act (Canada) on a capital gain realized on a disposition or deemed disposition of a security, unless the security is "taxable Canadian property" to the U.S. Holder for purposes of the Income Tax Act (Canada) and the U.S. Holder is not entitled to relief under the Tax Treaty.

  60

  ---

  Generally, our common shares will not constitute "taxable Canadian property" to a U.S. Holder at a particular time unless, at any time during the 60 month period immediately preceding the disposition, more than 50% of the fair market value of such security was derived, directly or indirectly, from one or any combination of: (i) real or immoveable property situated in Canada, (ii) "Canadian resource properties" (as defined in the Income Tax Act (Canada)), (iii) "timber resource properties" (as defined in the Income Tax Act (Canada)), and (iv) options in respect of, or interests in, or for civil law rights in, property described in any of the foregoing whether or not the property exists. Notwithstanding the foregoing, in certain other circumstances set out in the Income Tax Act (Canada), common shares could also be deemed to be "taxable Canadian property".

  If our common shares become listed on a "designated stock exchange" as defined in the Income Tax Act (Canada) and are so listed at the time of disposition, our common shares generally will not constitute "taxable Canadian property" of a U.S. Holder at that time unless, at any time during the 60 month period immediately preceding the disposition, the following two conditions are met: (i) the U.S. Holder, persons with whom the U.S. Holder did not deal at arm's length, partnerships in which the U.S. Holder or such non-arm's length person holds a membership interest (either directly or indirectly through one or more partnerships), or the U.S. Holder together with all such persons, owned 25% or more of the issued shares of any class or series of shares of our company; and (ii) more than 50% of the fair market value of the shares of our company was derived directly or indirectly from one or any combination of real or immovable property situated in Canada, Canadian resource properties (as defined in the Income Tax Act (Canada)), timber resource properties (as defined in the Income Tax Act (Canada)) or options in respect of, or interests in, or for civil law rights in, property described in any of the foregoing whether or not the property exists. Notwithstanding the foregoing, in certain other circumstances set out in the Income Tax Act (Canada), common shares could also be deemed to be "taxable Canadian property".

  54

  ---

  U.S. Holders who may hold common shares as "taxable Canadian property" should consult their own tax advisors with respect to the application of Canadian capital gains taxation, any potential relief under the Tax Treaty, and special compliance procedures under the Income Tax Act (Canada), none of which is described in this summary.

  Certain Material United States Federal Income Tax Considerations

  The following is a general summary of certain material U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from the acquisition, ownership and disposition of our common shares. This summary applies only to U.S. Holders that acquire our common shares pursuant to this prospectus and does not apply to any subsequent U.S. Holder of our common shares.

  This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder as a result of the acquisition, ownership and disposition of our common shares. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder, including specific tax consequences to a U.S. Holder under an applicable tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any particular U.S. Holder. In addition, this summary does not address the U.S. federal alternative minimum, net investment income, U.S. federal estate and gift, U.S. Medicare contribution, U.S. state and local, or non-U.S. tax consequences of the acquisition, ownership or disposition of our common shares. Except as specifically set forth below, this summary does not discuss applicable tax reporting requirements.

  Each U.S. Holder should consult its own tax advisor regarding all U.S. federal, U.S. state and local and non-U.S. tax consequences of the acquisition, ownership and disposition of our common shares.

  No opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the "IRS") has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership or disposition of our common shares. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, or contrary to, any position taken in this summary. In addition, because the authorities upon which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the positions taken in this summary.

  61

  ---

  Scope of This Disclosure
  
  Authorities

  This summary is based on the Internal Revenue Code, as amended (the "Code"), Treasury Regulations (whether final, temporary, or proposed), published rulings of the IRS, published administrative positions of the IRS, the Convention Between Canada and the United States of America with Respect to Taxes on Income and on Capital, signed September 26, 1980, as amended (the "Canada-U.S. Tax Convention"), and U.S. court decisions that are applicable and, in each case, as in effect and available, as of the date hereof. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied on a retroactive or prospective basis, which could affect the U.S. federal income tax considerations described in this summary. This summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation that, if enacted, could be applied on a retroactive or prospective basis.

  U.S. Holders

  For purposes of this summary, the term "U.S. Holder" means a beneficial owner of our common shares that is for U.S. federal income tax purposes:

  • an individual who is a citizen or resident of the U.S.;

  • a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the U.S., any state thereof or the District of Columbia;

  • an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
   

  • a trust that

  55

  ---

  a. is subject to the primary supervision of a court within the U.S. and the control of one or more U.S. persons for all substantial decisions; or

  b. has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.

  ​U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed

  This summary does not address the U.S. federal income tax considerations of the acquisition, ownership or disposition of our common shares by U.S. Holders that are subject to special provisions under the Code, including, but not limited to, the following: (a) tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b) financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies; (c) broker-dealers, dealers, or traders in securities or currencies that elect to apply a "mark-to-market" accounting method; (d) U.S. Holders that have a "functional currency" other than the U.S. dollar; (e) U.S. Holders that own our common shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other arrangement involving more than one position; (f) U.S. Holders that acquire our common shares in connection with the exercise of employee stock options or otherwise as compensation for services; (g) U.S. Holders that hold our securities other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes); and (h) U.S. Holders that own directly, indirectly, or by attribution, 10% or more, by voting power, of our outstanding stock.

  This summary also does not address the U.S. federal income tax considerations applicable to U.S. Holders who are: (a) U.S. expatriates or former long-term residents of the U.S.; (b) persons that have been, are, or will be a resident or deemed to be a resident in Canada for purposes of the Income Tax Act (Canada); (c) persons that use or hold, will use or hold, or that are or will be deemed to use or hold our securities in connection with carrying on a business in Canada; (d) persons whose securities in our company constitute "taxable Canadian property" under the Income Tax Act (Canada); or (e) persons that have a permanent establishment in Canada for purposes of the Canada-U.S. Tax Convention. U.S. Holders that are subject to special provisions under the Code, including U.S. Holders described immediately above, should consult their own tax advisors regarding all U.S. federal, U.S. state and local, and non-U.S. tax consequences (including the potential application and operation of any income tax treaties) relating to the acquisition, ownership or disposition of our common shares.

  If an entity or arrangement that is classified as a partnership (or other "pass-through" entity) for U.S. federal income tax purposes holds our common shares, the U.S. federal income tax consequences to such partnership and the partners (or other owners) of such partnership of the acquisition, ownership or disposition of our common shares generally will depend on the activities of the partnership and the status of such partners (or other owners). This summary does not address the U.S. federal income tax considerations for any such partner or partnership (or other "pass-through" entity or its owners). Owners of entities and arrangements that are classified as partnerships (or other "pass-through" entities) for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences of the acquisition, ownership or disposition of our common shares.

  62

  ---

  Ownership and Disposition of Our Common Shares

  Distributions on Our Common Shares

  Subject to the "passive foreign investment company" ("PFIC") rules discussed below (see "Tax Consequences if Our Company is a PFIC"), a U.S. Holder that receives a distribution, including a constructive distribution, with respect to our common shares will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of the current or accumulated "earnings and profits" of our company, as computed for U.S. federal income tax purposes. To the extent that a distribution exceeds the current and accumulated "earnings and profits" of our company, such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder's tax basis in our common shares and thereafter as gain from the sale or exchange of such common shares (see "Sale or Other Taxable Disposition of Our Common Shares" below). However, we may not maintain calculations of earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder should therefore assume that any distribution by our company with respect to our common shares will constitute a dividend. Dividends received on our common shares generally will not be eligible for the "dividends received deduction" available to U.S. corporate shareholders receiving dividends from U.S. corporations. If our company is eligible for the benefits of the Canada-U.S. Tax Convention or our common shares is readily tradable on an established securities market in the U.S., dividends paid by our company to non-corporate U.S. Holders generally will be eligible for the preferential tax rates applicable to long-term capital gains, provided certain holding period and other conditions are satisfied, including that our company not be classified as a PFIC in the tax year of distribution or in the preceding tax year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisor regarding the application of such rules.

  56

  ---

  Sale or Other Taxable Disposition of Our Common Shares

  Subject to the PFIC rules discussed below, upon the sale or other taxable disposition of our common shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the amount of cash plus the fair market value of any property received and such U.S. Holder's tax basis in the common shares sold or otherwise disposed of. Such capital gain or loss will be long-term capital gain or loss if, at the time of the sale or other taxable disposition, the U.S. Holder's holding period for such security is more than one year. Preferential tax rates apply to long-term capital gains of non-corporate U.S. Holders. There are currently no preferential tax rates for long-term capital gains of a U.S. Holder that is a corporation. Deductions for capital losses are subject to significant limitations under the Code.

  PFIC Status of Our Company

  If our company is or becomes a PFIC, the preceding sections of this summary may not describe the U.S. federal income tax consequences to U.S. Holders of the ownership and disposition of our common shares. The U.S. federal income tax consequences of owning and disposing of our common shares if our company is or becomes a PFIC are described below under the heading "Tax Consequences if Our Company is a PFIC."

  A non-U.S. corporation is a PFIC for each tax year in which (i) 75% or more of its gross income is passive income (as defined for U.S. federal income tax purposes) (the "income test") or (ii) on average for such tax year, 50% or more (by value) of its assets either produces or is held for the production of passive income (the "asset test"). For purposes of the PFIC provisions, "gross income" generally includes sales revenues less cost of goods sold, plus income from investments and from incidental or outside operations or sources, and "passive income" generally includes dividends, interest, certain rents and royalties, and certain gains from commodities or securities transactions. In determining whether or not it is a PFIC, a non-U.S. corporation is required to take into account its pro rata portion of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value).

  Under certain attribution and indirect ownership rules, if our company is a PFIC, U.S. Holders will generally be deemed to own their proportionate shares of our company's direct or indirect equity interest in any company that is also a PFIC (a "Subsidiary PFIC").

  63

  ---

  Our Company does not know if it currently is a PFIC or was a PFIC in a prior year and, based on current business plans and financial projections, does not know if it will be a PFIC in subsequent tax years. The determination of PFIC status is inherently factual, is subject to a number of uncertainties, and can be determined only annually after the close of the tax year in question. Additionally, the analysis depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. We might be determined to be a PFIC for the current tax year or any prior or future tax year, and no opinion of legal counsel or ruling from the IRS concerning the status of our company as a PFIC has been obtained or will be requested. U.S. Holders should consult their own U.S. tax advisors regarding the PFIC status of our company.

  Tax Consequences if Our Company is a PFIC

  If our company is a PFIC for any tax year during which a U.S. Holder owns our common shares, special rules may increase such U.S. Holder's U.S. federal income tax liability with respect to the ownership and disposition of such common shares. If our company meets the income test or the asset test for any tax year during which a U.S. Holder owns our common shares, our company will be treated as a PFIC with respect to such U.S. Holder for that tax year and for all subsequent tax years, regardless of whether our company meets the income test or the asset test for such subsequent tax years, unless the U.S. Holder elects to recognize any unrealized gain in such common shares or makes a timely and effective QEF Election or, if applicable, Mark-to-Market Election.

  Under the default PFIC rules:

  • • any gain realized on the sale or other disposition (including dispositions and certain other events that would not otherwise be treated as taxable events) of our common shares (including an indirect disposition of the stock of any Subsidiary PFIC) and any "excess distribution" (defined as a distribution to the extent it, together with all other distributions received in the relevant tax year, exceeds 125% of the average annual distribution received during the preceding three years) received on our common shares or with respect to the stock of a Subsidiary PFIC will be allocated ratably to each day of such U.S. Holder's holding period for our common shares;

    
     

  • 57